Unnamed: 0,title,date,stock,sentiment
651192.0,"Benzinga's Top Upgrades, Downgrades For June 5, 2020",2020-06-05 09:56:00-04:00,ICPT,positive
651193.0,"BMO Capital Initiates Coverage On Intercept Pharmaceuticals with Outperform Rating, Announces Price Target of $107",2020-06-05 06:50:00-04:00,ICPT,neutral
651194.0,Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates,2020-06-01 16:00:00-04:00,ICPT,neutral
651195.0,71 Biggest Movers From Friday,2020-05-26 04:30:00-04:00,ICPT,neutral
651196.0,46 Stocks Moving In Friday's Mid-Day Session,2020-05-22 12:45:00-04:00,ICPT,neutral
651197.0,Hearing Raymond James Downgraded Intercept Pharmaceuticals From Strong Buy To Outperform; Unconfirmed,2020-05-22 10:38:00-04:00,ICPT,positive
651198.0,Intercept Notified BY FDA That AdCom Meeting For Obeticholic Acid NDA Has Been Postponed,2020-05-22 08:04:00-04:00,ICPT,negative
651199.0,"Stifel Maintains Hold on Intercept Pharmaceuticals, Lowers Price Target to $99",2020-05-12 09:28:00-04:00,ICPT,negative
651200.0,Recap: Intercept Pharmaceuticals Q1 Earnings,2020-05-11 09:55:00-04:00,ICPT,neutral
651201.0,"Intercept Pharmaceuticals Q1 EPS $(2.860) Beats $(2.950) Estimate, Sales $72.652M Beat $69.660M Estimate",2020-05-11 07:21:00-04:00,ICPT,neutral
651202.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,ICPT,neutral
651203.0,Analyst Projects Over 130% Upside In This Biopharma,2020-04-07 10:59:00-04:00,ICPT,neutral
651204.0,"Benzinga's Top Upgrades, Downgrades For April 2, 2020",2020-04-02 09:35:00-04:00,ICPT,positive
651205.0,"Chardan Capital Initiates Coverage On Intercept Pharmaceuticals with Buy Rating, Announces Price Target to $145",2020-04-02 06:44:00-04:00,ICPT,neutral
651206.0,"Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors.",2020-03-26 11:49:00-04:00,ICPT,positive
651207.0,"Intercept Pharmaceuticals Inc Says Prescription Drug User Fee Act Target Action Date For NDA Remains June 26, 2020",2020-03-26 08:11:00-04:00,ICPT,neutral
651208.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,ICPT,neutral
651209.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,ICPT,positive
651210.0,"Benzinga's Top Upgrades, Downgrades For March 5, 2020",2020-03-05 10:05:00-05:00,ICPT,positive
651211.0,"B of A Securities Initiates Coverage On Intercept Pharmaceuticals with Neutral Rating, Announces $111 Price Target",2020-03-05 06:32:00-05:00,ICPT,positive
651212.0,Citigroup Upgrades Intercept Pharmaceuticals to Buy,2020-02-26 05:10:00-05:00,ICPT,neutral
651213.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,ICPT,negative
651214.0,"Intercept Pharmaceuticals Q4 EPS $(2.99) Misses $(2.62) Estimate, Sales $71.5M Beat $68.42M Estimate",2020-02-25 07:11:00-05:00,ICPT,negative
651215.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,ICPT,neutral
651216.0,SVB Leerink Upgrades Intercept Pharmaceuticals to Market Perform,2020-02-21 10:02:00-05:00,ICPT,neutral
651217.0,13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market,2020-02-05 16:11:00-05:00,ICPT,neutral
651218.0,"The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut",2020-01-29 08:30:00-05:00,ICPT,neutral
651219.0,Intercept Reports Completion Of Enrollment For Phase 3 REVERSE Study Evaluating Obeticholic Acid For Treatment Of Compensated Cirrhosis Due To NASH,2020-01-29 08:04:00-05:00,ICPT,neutral
651220.0,"Intercept 8-K Shows FDA Notified Co. Of Extension For PDUFA Target Action Date To Jun. 26, 2020",2020-01-17 08:11:00-05:00,ICPT,neutral
651221.0,"B. Riley FBR Maintains Buy on Intercept Pharmaceuticals, Raises Price Target to $158",2020-01-09 13:50:00-05:00,ICPT,neutral
651222.0,"Citi Downgrades Intercept, Says NASH Launch Is Appropriately Priced In",2020-01-02 12:40:00-05:00,ICPT,neutral
651223.0,10 Biggest Price Target Changes For Thursday,2020-01-02 08:20:00-05:00,ICPT,neutral
651224.0,"Citigroup Downgrades Intercept Pharmaceuticals to Neutral, Raises Price Target to $140",2020-01-02 06:14:00-05:00,ICPT,neutral
651225.0,"Credit Suisse Maintains Outperform on Intercept Pharmaceuticals, Raises Price Target to $141",2019-12-17 09:49:00-05:00,ICPT,positive
651226.0,"Wells Fargo Maintains Overweight on Intercept Pharmaceuticals, Raises Price Target to $146",2019-12-17 09:47:00-05:00,ICPT,negative
651227.0,"Intercept Pharma Offers Regulatory Update: Co. Submitted Marketing Authorization Application To EMA, FDA Notified Co. Of Tentative Date For AdCom Panel As Apr. 22, 2020",2019-12-13 08:03:00-05:00,ICPT,neutral
651228.0,74 Biggest Movers From Friday,2019-12-09 05:22:00-05:00,ICPT,neutral
651229.0,55 Stocks Moving In Friday's Mid-Day Session,2019-12-06 12:02:00-05:00,ICPT,neutral
651230.0,Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet,2019-12-06 05:30:00-05:00,ICPT,neutral
651231.0,45 Biggest Movers From Yesterday,2019-11-26 07:05:00-05:00,ICPT,neutral
651232.0,33 Stocks Moving In Monday's Mid-Day Session,2019-11-25 12:28:00-05:00,ICPT,neutral
651233.0,36 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-11-25 08:40:00-05:00,ICPT,neutral
651234.0,"Intercept Pharma Reports FDA Accepted New Drug Application For Obeticholic Acid For Treatment Of Liver Fibrosis Due To NASH, Has Granted Priority Review",2019-11-25 08:01:00-05:00,ICPT,positive
651235.0,"UBS Maintains Buy on Intercept Pharmaceuticals, Lowers Price Target to $135",2019-11-12 07:50:00-05:00,ICPT,negative
651236.0,"RBC Capital Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to $134",2019-11-06 08:36:00-05:00,ICPT,negative
651237.0,"Intercept Pharmaceuticals Q3 EPS $(2.59) Misses $(2.43) Estimate, Sales $61.95M Miss $63.33M Estimate",2019-11-05 07:56:00-05:00,ICPT,negative
651238.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,ICPT,negative
651239.0,Hearing Dealreporter Says Gilead Could Be Eyeing Intercept Pharma,2019-10-25 09:38:00-04:00,ICPT,neutral
651240.0,"Raymond James Maintains Strong Buy on Intercept Pharmaceuticals, Lowers Price Target to $147",2019-10-21 08:09:00-04:00,ICPT,positive
651241.0,Stocks That Hit 52-Week Lows On Thursday,2019-10-10 11:08:00-04:00,ICPT,negative
651242.0,"The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO",2019-10-10 07:31:00-04:00,ICPT,neutral
651243.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-08 12:02:00-04:00,ICPT,negative
651244.0,Intercept Pharma Reports Submitted New Drug Application For Obeticholic Acid in Patients with Fibrosis Due to NASH,2019-09-27 16:05:00-04:00,ICPT,neutral
651245.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,ICPT,neutral
651246.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,ICPT,negative
651247.0,"Benzinga's Top Upgrades, Downgrades For September 4, 2019",2019-09-04 11:01:00-04:00,ICPT,positive
651248.0,"Citigroup Upgrades Intercept Pharmaceuticals to Buy, Lowers Price Target to $85",2019-09-04 06:24:00-04:00,ICPT,negative
651249.0,"Intercept Pharmaceuticals, Inc.: Akkaraju Srinivas (Director) Buys 5,207 @ Avg Price: $60.32",2019-08-30 14:35:00-04:00,ICPT,neutral
651250.0,Intercept Pharma shares continuing higher following Q2 earnings Wednesday morning. Shares have broken above the $62 level today.,2019-08-08 14:46:00-04:00,ICPT,positive
651251.0,"Cantor Fitzgerald Reiterates Overweight on Intercept Pharmaceuticals, Lowers Price Target to $186",2019-08-08 07:57:00-04:00,ICPT,negative
651252.0,"Intercept Pharmaceuticals Q2 EPS $(2.28) Beats $(2.6) Estimate, Sales $66.3M Beat $58.6M Estimate",2019-08-07 07:56:00-04:00,ICPT,neutral
651253.0,"The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout",2019-08-07 07:34:00-04:00,ICPT,neutral
651254.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,ICPT,positive
651255.0,New 52-Week Lows For Monday Morning,2019-08-05 13:16:00-04:00,ICPT,negative
651256.0,Stocks That Set New 52-Week Lows Friday Morning,2019-08-02 10:46:00-04:00,ICPT,negative
651257.0,Stocks that Reached Yearly Lows Thursday Morning,2019-08-01 11:09:00-04:00,ICPT,negative
651258.0,"The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings",2019-08-01 07:18:00-04:00,ICPT,negative
651259.0,New 52-Week Low Achievers For Wednesday Morning,2019-07-31 11:16:00-04:00,ICPT,negative
651260.0,Stocks That Managed to Breach 52-Week Lows Friday,2019-07-26 15:45:00-04:00,ICPT,negative
651261.0,"The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint",2019-07-26 07:26:00-04:00,ICPT,neutral
651262.0,List of Companies Reaching Yearly Lows Tuesday,2019-07-23 14:58:00-04:00,ICPT,neutral
651263.0,"The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation",2019-07-23 07:26:00-04:00,ICPT,negative
651264.0,"The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study",2019-07-12 07:24:00-04:00,ICPT,negative
651265.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,ICPT,negative
651266.0,50 Biggest Movers From Yesterday,2019-07-11 05:19:00-04:00,ICPT,neutral
651267.0,40 Stocks Moving In Wednesday's Mid-Day Session,2019-07-10 12:17:00-04:00,ICPT,neutral
651268.0,"Stifel Nicolaus Initiates Coverage On Intercept Pharmaceuticals with Hold Rating, Announces $89 Price Target",2019-06-25 06:45:00-04:00,ICPT,neutral
651269.0,ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis Prevention,2019-06-17 13:50:00-04:00,ICPT,neutral
651270.0,Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.,2019-06-17 10:10:00-04:00,ICPT,positive
651271.0,"Intecept Pharma Shares Spike To Session High On Volume As Hearing RBC Commented On Recent Co. CEO Communication With FDA, Definitive Confirmation Histological Endpoints Can Still Form Basis Of Accelerated Approval From Its REVERSE Study",2019-06-13 15:21:00-04:00,ICPT,positive
651272.0,"Why Low-Float, Thinly Traded ContraVir Pharma's Rally Is Continuing",2019-06-11 14:29:00-04:00,ICPT,neutral
651273.0,"Baird Out Defending Intercept Pharmaceuticals, Says 'sharp selloff in shares on FDA Draft guidance that doesn't even address the primary commercial opportunity for OCA is silly'",2019-06-06 14:32:00-04:00,ICPT,positive
651274.0,ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study,2019-06-06 11:44:00-04:00,ICPT,neutral
651275.0,Intercept Pharma Shares Saw Mid-Day Parabolic Move On Very Large Uptick In Volume Amid Report RBC Suggested The Co. Could Be Worth $142/Share In A Takeout,2019-05-23 13:40:00-04:00,ICPT,positive
651276.0,"The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",2019-05-09 07:56:00-04:00,ICPT,neutral
651277.0,Intercept Pharma Reports $200M Common Stock Offering,2019-05-08 17:16:00-04:00,ICPT,neutral
651278.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,ICPT,negative
651279.0,Intercept Pharmaceuticals Sees 2019 Ocaliva Sales $235M-$245M,2019-05-08 07:10:00-04:00,ICPT,neutral
651280.0,"Intercept Pharmaceuticals Q1 EPS $(3.03) Misses $(2.52) Estimate, Sales $51.85M Beat $51.8M Estimate",2019-05-08 07:08:00-04:00,ICPT,negative
651281.0,"Benzinga's Top Upgrades, Downgrades For May 3, 2019",2019-05-03 08:53:00-04:00,ICPT,positive
651282.0,"Wells Fargo Upgrades Intercept Pharmaceuticals, Inc. - Common Stock to Outperform",2019-05-03 06:26:00-04:00,ICPT,positive
651283.0,Gilead Reiterates Faith In NASH Combination Approach After Another Trial Disappointment,2019-04-25 10:13:00-04:00,ICPT,negative
651284.0,"Wells Fargo Maintains Market Perform on Intercept Pharmaceuticals, Raises Price Target to $104",2019-04-12 10:35:00-04:00,ICPT,positive
651285.0,50 Biggest Movers From Yesterday,2019-04-12 05:22:00-04:00,ICPT,neutral
651286.0,36 Stocks Moving In Thursday's Mid-Day Session,2019-04-11 12:23:00-04:00,ICPT,neutral
651287.0,Is Intercept Pharma's Updated Late-Stage NASH Data A Sell-The-News Event?,2019-04-11 11:26:00-04:00,ICPT,neutral
651288.0,Intercept Pharmaceuticals Option Alert: Jun 21 $140 Calls at the Ask: 600 @ $2.5 vs 1718 OI; Earnings 5/7 Before Open [est] Ref=$107.9022,2019-04-11 09:57:00-04:00,ICPT,positive
651289.0,"Intercept Pharmaceuticals shares are trading lower, despite the company reporting additional positive data from its REGENERATE phase 3 study in NASH, after investors interpreted this data to be underwhelming and not have much new information.",2019-04-11 09:51:00-04:00,ICPT,positive
651290.0,'$ICPT — Anyone else disappointed w/ this morning's NASH study update? Not much new to chew over. The per protocol efficacy results seem like marketing material. Safety data essentially same as previously disclosed. Am I missing something?' -STAT's Adam F,2019-04-11 09:10:00-04:00,ICPT,neutral
651291.0,28 Stocks Moving In Thursday's Pre-Market Session,2019-04-11 08:03:00-04:00,ICPT,neutral
651292.0,"The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug",2019-04-11 07:48:00-04:00,ICPT,positive
651293.0,"Intercept Reports Additional Positive Data from REGENERATE, the First Successful Phase 3 Study in NASH",2019-04-11 03:44:00-04:00,ICPT,positive
651294.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts",2019-04-07 17:04:00-04:00,ICPT,neutral
651295.0,Intercept To Present Results From Phase 3 Trial Patients with Liver Fibrosis Due to NASH at the International Liver Congress™ 2019,2019-04-04 07:04:00-04:00,ICPT,neutral
651296.0,Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo,2019-03-22 10:49:00-04:00,ICPT,neutral
651297.0,36 Stocks Moving In Tuesday's Pre-Market Session,2019-03-19 08:10:00-04:00,ICPT,neutral
651298.0,Intercept Pharmaceuticals Option Alert: Mar 15 $109 Calls at the Ask: 846 @ $4.401 vs 1018 OI; Ref=$105.96,2019-03-01 14:28:00-05:00,ICPT,positive
651299.0,"Raymond James Maintains Strong Buy on Intercept Pharmaceuticals, Raises Price Target to $187",2019-03-01 10:08:00-05:00,ICPT,positive
651300.0,"B. Riley FBR Maintains Buy on Intercept Pharmaceuticals, Raises Price Target to $169",2019-03-01 09:33:00-05:00,ICPT,neutral
651301.0,"Benzinga's Top Upgrades, Downgrades For March 1, 2019",2019-03-01 09:01:00-05:00,ICPT,positive
651302.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Mar. 1, 2019",2019-03-01 08:55:00-05:00,ICPT,positive
651303.0,RBC Capital Upgrades Intercept Pharmaceuticals to Outperform,2019-03-01 06:55:00-05:00,ICPT,neutral
651304.0,75 Biggest Movers From Yesterday,2019-03-01 04:55:00-05:00,ICPT,neutral
651305.0,"Cantor Fitzgerald Reiterates Overweight on Intercept Pharmaceuticals, Raises Price Target to $191",2019-02-28 13:58:00-05:00,ICPT,negative
651306.0,51 Stocks Moving In Thursday's Mid-Day Session,2019-02-28 12:28:00-05:00,ICPT,neutral
651307.0,"Intercept Pharmaceuticals Inc shares are trading higher after the company beat Q4 sales estimates, despite missing on EPS; the company guided FY19 Ocaliva sales of $225 million to $240 million.",2019-02-28 11:24:00-05:00,ICPT,positive
651308.0,Intercept Sees FY19 Ocaliva Sales $225M-$240M,2019-02-28 09:06:00-05:00,ICPT,neutral
651309.0,"Intercept Pharmaceuticals Q4 EPS $(2.97) Misses $(2.47) Estimate, Sales $53.28M Beat $52.28M Estimate",2019-02-28 09:06:00-05:00,ICPT,negative
651310.0,"'$ICPT says eDISH plot for REGENERATE looks v similar to FLINT. 3 on pbo entered Hy's law quadrant, vs total of 3 btwn low/high dose OCA' -Tweet From Notable FDA Source",2019-02-28 09:05:00-05:00,ICPT,neutral
651311.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,ICPT,positive
651312.0,Intercept Pharmaceuticals Option Alert: Mar 1 $100 Calls at the Ask: 600 @ $2.0 vs 42 OI; Earnings 2/25 Before Open [est] Ref=$90.9199,2019-02-21 14:35:00-05:00,ICPT,positive
651313.0,"Citigroup Maintains Neutral on Intercept Pharmaceuticals, Raises Price Target to $140",2019-02-21 07:51:00-05:00,ICPT,neutral
651314.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Thurs., Feb. 21, 2019",2019-02-21 06:49:00-05:00,ICPT,positive
651315.0,75 Biggest Movers From Yesterday,2019-02-21 05:12:00-05:00,ICPT,neutral
651316.0,Adam Feuerstein of Stat News Tweets on Intercept Pharma,2019-02-20 13:06:00-05:00,ICPT,neutral
651317.0,7 Biggest Price Target Changes For Wednesday,2019-02-20 10:05:00-05:00,ICPT,neutral
651318.0,71 Biggest Movers From Yesterday,2019-02-20 04:49:00-05:00,ICPT,neutral
651319.0,"Wedbush Maintains Outperform on Intercept Pharmaceuticals, Raises Price Target From $220 To $248",2019-02-19 14:35:00-05:00,ICPT,neutral
651320.0,54 Stocks Moving In Tuesday's Mid-Day Session,2019-02-19 13:01:00-05:00,ICPT,neutral
651321.0,Intercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial,2019-02-19 10:36:00-05:00,ICPT,positive
651322.0,Mid-Morning Market Update: Markets Edge Higher; Walmart Tops Q4 Expectations,2019-02-19 10:15:00-05:00,ICPT,positive
651323.0,Intercept Pharmaceuticals shares are trading higher after the company reported its Phase 3 REGENERATE study of obleticholic acid patients with NASH-related liver fibrosis met its primary endpoint.,2019-02-19 08:49:00-05:00,ICPT,positive
651324.0,25 Stocks Moving In Tuesday's Pre-Market Session,2019-02-19 08:12:00-05:00,ICPT,neutral
651325.0,Intercept Pharmaceuticals Reports Pivotal Phase 3 REGENERATE Study Of Obeticholic Acid Patients With NASH-Related Liver Fibrosis Met Primary Endpoint,2019-02-19 07:20:00-05:00,ICPT,neutral
651326.0,Analyst: Intercept's NASH Drug Could Launch Sans Competition After Gilead Trial Failure,2019-02-13 16:22:00-05:00,ICPT,negative
651327.0,Intercept Pharamceuticals shares are trading down after Gilead's disappointing NASH trial results; Intercept is also developing a NASH candidate and may be trading down in sympathy with Gilead.,2019-02-12 15:16:00-05:00,ICPT,positive
651328.0,"Gilead Analysts React To Failed NASH Trial: Citigroup, Wells Fargo Downgrade Biotech",2019-02-12 12:12:00-05:00,ICPT,negative
651329.0,Gilead's Failed NASH Drug Trial Drags Stock Lower,2019-02-12 09:07:00-05:00,ICPT,negative
651330.0,Intercept Pharmaceuticals shares are trading higher after Raymond James upgraded the stock from Outperform to Strong Buy.,2019-02-04 11:51:00-05:00,ICPT,positive
651331.0,"Benzinga's Top Upgrades, Downgrades For February 4, 2019",2019-02-04 09:09:00-05:00,ICPT,positive
651332.0,Raymond James Upgrades Intercept Pharmaceuticals to Strong Buy,2019-02-04 07:41:00-05:00,ICPT,positive
651333.0,"Benzinga's Top Upgrades, Downgrades For January 31, 2019",2019-01-31 09:11:00-05:00,ICPT,positive
651334.0,"Credit Suisse Initiates Coverage On Intercept Pharmaceuticals with Outperform Rating, Announces $167 Price Target",2019-01-31 07:35:00-05:00,ICPT,positive
651335.0,JMP Upgrades Intercept Pharma Ahead Of NASH Trial Data,2019-01-30 16:00:00-05:00,ICPT,neutral
651336.0,"Benzinga's Top Upgrades, Downgrades For January 30, 2019",2019-01-30 09:17:00-05:00,ICPT,positive
651337.0,"JMP Securities Upgrades Intercept Pharmaceuticals to Market Outperform, Announces $175 Price Target",2019-01-30 06:26:00-05:00,ICPT,positive
651338.0,"Needham Upgrades Intercept Pharmaceuticals to Buy, Announces $150 Price Target",2019-01-24 07:52:00-05:00,ICPT,neutral
651339.0,"Benzinga's Top Upgrades, Downgrades For January 23, 2019",2019-01-23 09:14:00-05:00,ICPT,positive
651340.0,UBS Initiates Coverage On Intercept Pharmaceuticals with Buy Rating,2019-01-23 08:33:00-05:00,ICPT,neutral
651341.0,Intercept Pharmaceuticals Option Alert: Mar 15 $150 Calls at the Ask: 750 @ $9.6 vs 558 OI; Earnings 2/13 Before Open [est] Ref=$112.97,2019-01-22 11:16:00-05:00,ICPT,positive
651342.0,Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year,2019-01-18 09:15:00-05:00,ICPT,neutral
651343.0,"Laidlaw & Co. Upgrades Intercept Pharmaceuticals to Buy, Raises Price Target to $130",2019-01-14 09:46:00-05:00,ICPT,neutral
651344.0,"Intercept Pharma Says it Expects To Read-Out Top-Line Data From the Interim Analysis of its Phase 3 REGENERATE Trial in Q1 2019, Plans to Complete Enrollment of its Phase 3 REVERSE Trial in 2019",2019-01-07 07:04:00-05:00,ICPT,neutral
651345.0,Raymond James: Gilead In NASH For The Long Haul,2018-12-20 09:43:00-05:00,ICPT,neutral
651346.0,"Intercept Pharmaceuticals Option Alert: Jan, 2020 $70 Calls Sweep (4) near the Ask: 525 @ $57.0 vs 547 OI; Ref=$112.73",2018-12-13 10:48:00-05:00,ICPT,positive
651347.0,"Benzinga's Top Upgrades, Downgrades For December 12, 2018",2018-12-12 09:28:00-05:00,ICPT,positive
651348.0,"B. Riley FBR Initiates Coverage On Intercept Pharmaceuticals with Buy Rating, Announces $155 Price Target",2018-12-12 09:10:00-05:00,ICPT,neutral
651349.0,"Oppenheimer Upgrades Intercept Pharmaceuticals to Outperform, Announces $140 Price Target",2018-11-19 06:10:00-05:00,ICPT,neutral
651350.0,"The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut",2018-10-31 08:20:00-04:00,ICPT,negative
651351.0,Intercept Reaffirms FY18 Ocaliva Sales $170M-$185M,2018-10-31 07:43:00-04:00,ICPT,neutral
651352.0,Intercept Pharmaceuticals Reaffirms FY18 Octavia Net Sales Guidance Of $170M-$185M,2018-10-31 07:27:00-04:00,ICPT,neutral
651353.0,"Intercept Q3 EPS $(2.18) Beats $(2.55) Estimate, Sales $46.986M Miss $48.46M Estimate",2018-10-31 07:26:00-04:00,ICPT,negative
651354.0,45 Biggest Movers From Yesterday,2018-10-03 05:40:00-04:00,ICPT,neutral
651355.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-10-02 13:51:00-04:00,ICPT,neutral
651356.0,10 Biggest Price Target Changes For Tuesday,2018-10-02 09:48:00-04:00,ICPT,neutral
651357.0,"Benzinga's Top Upgrades, Downgrades For October 2, 2018",2018-10-02 09:46:00-04:00,ICPT,positive
651358.0,"Stocks Which Set New 52-Week High Yesterday, October 1st",2018-10-02 09:20:00-04:00,ICPT,neutral
651359.0,"Raymond James Downgrades Intercept Pharmaceuticals to Outperform, Raises Price Target to $141",2018-10-02 07:28:00-04:00,ICPT,neutral
651360.0,"Cantor Fitzgerald Assumes Intercept Pharmaceuticals at Overweight, Announces $170 Price Target",2018-10-01 08:22:00-04:00,ICPT,negative
651361.0,"The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results",2018-09-28 08:10:00-04:00,ICPT,positive
651362.0,Intercept Pharmaceuticals Option Alert: Dec 21 $120 Calls Sweep (200) near the Bid: 563 @ $14.501 vs 1252 OI; Earnings 10/31 Before Open [est] Ref=$116.8732,2018-09-21 11:10:00-04:00,ICPT,positive
651363.0,"Stocks Which Set New 52-Week High Friday, September 14th",2018-09-17 09:28:00-04:00,ICPT,neutral
651364.0,"Benzinga's Top Upgrades, Downgrades For September 12, 2018",2018-09-12 09:15:00-04:00,ICPT,positive
651365.0,"Roth Capital Initiates Coverage On Intercept Pharmaceuticals with Buy Rating, Announces $192 Price Target",2018-09-12 07:57:00-04:00,ICPT,neutral
651366.0,60 Biggest Movers From Yesterday,2018-08-16 04:56:00-04:00,ICPT,neutral
651367.0,"RBC Downgrades Intercept Pharma On Valuation, Remains Positive On Upcoming Trial Data",2018-08-15 13:57:00-04:00,ICPT,positive
651368.0,55 Stocks Moving In Wednesday's Mid-Day Session,2018-08-15 12:40:00-04:00,ICPT,neutral
651369.0,"Benzinga's Top Upgrades, Downgrades For August 15, 2018",2018-08-15 09:10:00-04:00,ICPT,positive
651370.0,RBC Capital Downgrades Intercept Pharmaceuticals to Sector Perform,2018-08-15 08:06:00-04:00,ICPT,neutral
651371.0,"Hearing RBC Says Earlier Reports Of Intercept's Ocaliva Deaths Reported In AERS Is In Line With Historicals, Says There's No Need For Concern",2018-08-07 12:47:00-04:00,ICPT,negative
651372.0,52 Biggest Movers From Yesterday,2018-08-07 05:19:00-04:00,ICPT,neutral
651373.0,Intercept Pharma Notches 2 Upgrades On Ocaliva Prospects,2018-08-06 12:44:00-04:00,ICPT,positive
651374.0,44 Stocks Moving In Monday's Mid-Day Session,2018-08-06 12:39:00-04:00,ICPT,neutral
651375.0,10 Biggest Price Target Changes For Monday,2018-08-06 09:40:00-04:00,ICPT,neutral
651376.0,"Benzinga's Top Upgrades, Downgrades For August 6, 2018",2018-08-06 09:13:00-04:00,ICPT,positive
651377.0,"Intercept Pharmaceuticals shares are up 6.2% premarket following bullish analyst activity Monday morning; Wedbush raised price target from $203-$217 and Goldman Sachs upgraded the stock from ""Sell"" to ""Buy"".",2018-08-06 08:51:00-04:00,ICPT,positive
651378.0,"Goldman Sachs Upgrades Intercept Pharmaceuticals From Sell To Buy, Announces $157 Price Target",2018-08-06 08:10:00-04:00,ICPT,neutral
651379.0,26 Stocks Moving In Monday's Pre-Market Session,2018-08-06 08:04:00-04:00,ICPT,neutral
651380.0,"Wedbush Maintains Outperform on Intercept Pharmaceuticals, Raises Price Target to $217",2018-08-06 08:00:00-04:00,ICPT,neutral
651381.0,"Laidlaw & Co. Downgrades Intercept Pharmaceuticals to Hold, Raises Price Target to $95",2018-08-03 09:17:00-04:00,ICPT,neutral
651382.0,"Intercept Pharmaceuticals Q2 EPS $(2.58) Beats $(2.84) Estimate, Sales $43.58M Beat $41.19M Estimate",2018-08-02 07:17:00-04:00,ICPT,neutral
651383.0,"Benzinga's Top Upgrades, Downgrades For June 28, 2018",2018-06-28 09:08:00-04:00,ICPT,positive
651384.0,"Raymond James Initiates Coverage On Intercept Pharmaceuticals with Strong Buy Rating, Announces $122 Price Target",2018-06-28 08:32:00-04:00,ICPT,positive
651385.0,"Viking Therapeutics Shares Spike ~4%, Intercept Pharma Shares Spike ~1.8% Following Report Madrigal Pharma Is Considering Sale",2018-06-13 11:24:00-04:00,ICPT,positive
651386.0,Intercept Pharma Shares Up 3.2%; Traders Circulating Word Bristol-Myers Could Be Interested In NASH Space,2018-06-08 09:39:00-04:00,ICPT,positive
651387.0,27 Stocks Moving In Thursday's Pre-Market Session,2018-06-07 08:20:00-04:00,ICPT,neutral
651388.0,Intercept Pharmaceuticals Sees FY2018 Ocaliva Sales $170.0M-185.0M vs $188.20M Est,2018-05-08 07:18:00-04:00,ICPT,neutral
651389.0,"Intercept Pharmaceuticals Q1 EPS $(3.22) Beats $(3.42) Estimate, Sales $35.963M Miss $38.94M Estimate",2018-05-08 07:17:00-04:00,ICPT,negative
651390.0,7 Biggest Price Target Changes For Tuesday,2018-04-17 09:42:00-04:00,ICPT,neutral
651391.0,"Wedbush Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to $203.00",2018-04-17 08:24:00-04:00,ICPT,negative
651392.0,"Insider Buys Of The Week: Intercept Pharmaceuticals, Macy's And More",2018-04-15 18:05:00-04:00,ICPT,neutral
651393.0,UPDATE: Intercept Offers Liver Biopsy Data from POISE Phase 3 Substudy Supports Obeticholic Acid's Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients,2018-04-13 07:02:00-04:00,ICPT,positive
651394.0,Intercept Pharma Reports Liver Biopsy Data From POISE Phase 3 Substudy: '11 of 13 patients improved or maintained histological fibrosis stage after three years of treatment with OCA',2018-04-13 07:02:00-04:00,ICPT,positive
651395.0,Form 4 Filing Late Monday Showed Intercept Pharma Director Daniel Bradbury Bought 7.812K Shares at $64,2018-04-10 10:36:00-04:00,ICPT,positive
651396.0,"Intercept Pharmaceuticals CEO Mark Pruzanski Buys 7,812 @ Avg Price: $64.00",2018-04-09 19:50:00-04:00,ICPT,neutral
651397.0,34 Biggest Movers From Yesterday,2018-04-06 04:21:00-04:00,ICPT,neutral
651398.0,28 Stocks Moving In Thursday's Mid-Day Session,2018-04-05 12:58:00-04:00,ICPT,neutral
651399.0,Intercept Option Alert: May 18 $60 Puts at the Bid: 712 @ $1.95 vs 24 OI; Earnings 5/3 Before Open [est] Ref=$69.36,2018-04-05 10:41:00-04:00,ICPT,positive
651400.0,Intercept Pharmaceuticals Prices 2.34M Upsized Offering At $64/Share,2018-04-05 08:35:00-04:00,ICPT,neutral
651401.0,Benzinga Pro's 5 Stocks To Watch Today,2018-04-05 08:06:00-04:00,ICPT,neutral
651402.0,Intercept Pharma 8-K Late Wed. Night Showed Expectation For FY18 Total Ocaliva Prescriptions Filled To Be Consistent With FY17 Sales; Q1 Sales Expected To Be Slightly Lower Than Q1'17,2018-04-05 07:11:00-04:00,ICPT,negative
651403.0,"8 Stocks To Watch For April 5, 2018",2018-04-05 04:35:00-04:00,ICPT,neutral
651404.0,"Intercept Pharmaceuticals Announces $120M Offering Common Stock, $92M Private Placement Common Stock",2018-04-04 16:05:00-04:00,ICPT,neutral
651405.0,"UPDATE: Intercept Pharma Filing Shows No Terms Of Settlement, Includes Ruling Remains Subject To Appeal",2018-03-26 17:16:00-04:00,ICPT,negative
651406.0,Intercept Pharma 8-K Shows New York Supreme Court Granted Defendants' Motion To Dismiss With Prejudice Derivative Suit Purportedly Brought On Behalf Co.,2018-03-26 17:15:00-04:00,ICPT,positive
651407.0,26 Stocks Moving In Friday's Pre-Market Session,2018-03-09 08:07:00-05:00,ICPT,neutral
651408.0,"Intercept Pharma Says on Feb 13, Co, Sumitomo Dainippon Pharma Entered Into Amendment to Certain License Agreement Dated as of March 29, 2011 -8K",2018-02-16 17:25:00-05:00,ICPT,positive
651409.0,"BMO Capital Maintains Outperform on Intercept Pharmaceuticals Inc, Raises price target to $155.00",2018-02-15 09:44:00-05:00,ICPT,neutral
651410.0,"Intercept Pharmaceuticals Reports Q4 EPS $(4.43) vs $(3.55) Est., Sales $37.68M vs $39M Est.",2018-02-14 07:06:00-05:00,ICPT,neutral
651411.0,Intercept Reports Phase 3 REVERSE Trial Evaluating OCA for the Treatment of NASH Patients with Compensated Cirrhosis,2018-02-12 08:07:00-05:00,ICPT,neutral
651412.0,Intercept Announces Phase 3 REVERSE Trial Evaluating OCA for the Treatment of NASH Patients with Compensated Cirrhosis,2018-02-12 08:07:00-05:00,ICPT,neutral
651413.0,20 Stocks Moving In Wednesday's Pre-Market Session,2018-02-07 08:14:00-05:00,ICPT,neutral
651414.0,"Intercept Announces Updated U.S. Prescribing Information for Ocaliva, Says Hepactic Decompensation And Failure Have Been Reported In Patients With Advanced Cirrhosis When Ocaliva Was Dosed More Frequently Than Recommended Starting Dosage",2018-02-01 09:47:00-05:00,ICPT,negative
651415.0,Intercept Pharma Shares Moving Higher Premarket As Traders Circulating FDA.gov Alert 'adds Boxed Warning to highlight correct dosing of Ocaliva (obeticholic acid) for patients with a rare chronic liver disease',2018-02-01 09:11:00-05:00,ICPT,positive
651416.0,"Hearing Intercept Pharma's Ocaliva Defended At Deutsche Bank, Unconfirmed",2018-01-02 14:40:00-05:00,ICPT,negative
651417.0,Intercept Option Alert: Jan 19 $55 Puts Sweep (38) at the Bid: 715 @ $1.55 vs 326 OI; Ref=$58.66,2018-01-02 11:51:00-05:00,ICPT,positive
651418.0,Intercept Pharma 8-K Shows Co. Is 'shifting guidance for an announcement of the Phase 3 REVERSE trial in NASH patients with compensated cirrhosis from YE17 to 1Q18',2017-12-28 07:36:00-05:00,ICPT,neutral
651419.0,"Deutsche Bank Initiates Coverage On Intercept Pharmaceuticals with Buy Rating, Announces $106.00 Price Target",2017-12-13 08:39:00-05:00,ICPT,neutral
651420.0,"Benzinga's Top Upgrades, Downgrades For November 2, 2017",2017-11-02 09:13:00-04:00,ICPT,positive
651421.0,Cantor Fitzgerald Upgrades Intercept Pharmaceuticals to Neutral,2017-11-02 08:24:00-04:00,ICPT,neutral
651422.0,Laidlaw & Co. Upgrades Intercept Pharmaceuticals to Buy,2017-11-01 13:55:00-04:00,ICPT,neutral
651423.0,Hearing Laidlaw Upgrades Shares Of Intercept Pharma From Hold To Buy,2017-11-01 13:51:00-04:00,ICPT,positive
651424.0,"Intercept Pharma Reports Q3 EPS $(2.89) vs $(3.38) Est., Sales $41.334M vs $37M Est.",2017-11-01 07:10:00-04:00,ICPT,neutral
651425.0,Benzinga's Option Alert Recap From October 25,2017-10-25 16:35:00-04:00,ICPT,positive
651426.0,Inrtercept Option Alert: Dec 15 $65 Calls Sweep (3) at the Bid: 1100 @ $4.201 vs 124 OI; Ref=$60.55,2017-10-25 14:18:00-04:00,ICPT,positive
651427.0,Intercept  Reports OCA Phase 2AESOP Trial Met Primary Endpoint Of ALP Reduction At 24 Weeks,2017-10-23 16:02:00-04:00,ICPT,neutral
651428.0,Benzinga's Option Alert Recap From October 9,2017-10-09 16:31:00-04:00,ICPT,positive
651429.0,Intercept Option Alert: Oct 20 $80 Calls Sweep (2) at the Bid: 950 @ $0.801 vs 563 OI; Ref=$69.8,2017-10-09 14:06:00-04:00,ICPT,positive
651430.0,15 Biggest Mid-Day Losers For Friday,2017-10-06 12:36:00-04:00,ICPT,negative
651431.0,"Seaport Global Initiates Coverage On Intercept Pharmaceuticals with Buy Rating, Announces $136.00 Price Target",2017-10-06 09:56:00-04:00,ICPT,neutral
651432.0,"Benzinga's Top Upgrades, Downgrades For October 4, 2017",2017-10-04 09:24:00-04:00,ICPT,positive
651433.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-10-04 08:07:00-04:00,ICPT,neutral
651434.0,JMP Securities Downgrades Intercept Pharmaceuticals to Market Perform,2017-10-04 07:59:00-04:00,ICPT,positive
651435.0,"Adam Feuerstein Tweets: Trying again:

Best performers in Q3: $DMTX $MRNS $MYOK

Worst: $OTIC $AXON $ICPT",2017-09-29 16:24:00-04:00,ICPT,neutral
651436.0,16 Stocks Moving In Friday's Pre-Market Session,2017-09-29 09:02:00-04:00,ICPT,neutral
651437.0,"Adam Feuerstein Tweets: Doctor invited to speak on $ICPT call making very impassioned defense of Ocaliva in PBC. He should disclose his financial conflicts, if any.",2017-09-25 09:02:00-04:00,ICPT,negative
651438.0,20 Stocks Moving In Monday's Pre-Market Session,2017-09-25 08:07:00-04:00,ICPT,neutral
651439.0,"Intercept Statement Regarding Ocaliva Safety and Dosing in Primary Biliary Cholangitis (PBC) Patients, Says Patients Were Prescribed 7 Times Higher Than Weekly Recommended Doses; Intercept And FDA Issued Safety Communication To Reinforce Label Dosing",2017-09-25 07:09:00-04:00,ICPT,positive
651440.0,Oppenheimer Downgrades Intercept Pharmaceuticals to Perform,2017-09-22 13:50:00-04:00,ICPT,neutral
651441.0,12 Biggest Mid-Day Losers For Friday,2017-09-22 12:34:00-04:00,ICPT,negative
651442.0,5 Biggest Price Target Changes For Friday,2017-09-22 12:07:00-04:00,ICPT,neutral
651443.0,Mid-Day Market Update: Revolution Lighting Technologies Drops Following Reduced FY2017 Outlook; Ascendis Pharma Shares Surge,2017-09-22 12:00:00-04:00,ICPT,positive
651444.0,FDA Letter On Intercept Pharma Doesn't Include Black Box Warning Label...Yet,2017-09-22 11:19:00-04:00,ICPT,negative
651445.0,Will Intercept Stock Potential Be Blindsided By FDA Letter?,2017-09-22 10:11:00-04:00,ICPT,neutral
651446.0,Intercept Pharma Shares Continuing Lower Fri. Following 26% Decline Thurs. Amid Report Of An FDA Warning Letter; Stock Down 13.6% Just After Open; Citi Downgraded Stock To Neutral Earlier,2017-09-22 09:40:00-04:00,ICPT,negative
651447.0,Citigroup Downgrades Intercept Pharmaceuticals to Neutral,2017-09-22 09:38:00-04:00,ICPT,neutral
651448.0,FDA Warning Letter Buckles Intercept Pharma Shares; Wells Fargo Downgrades,2017-09-22 09:13:00-04:00,ICPT,positive
651449.0,Wells Fargo Downgrades Intercept Pharmaceuticals to Market Perform,2017-09-21 15:02:00-04:00,ICPT,positive
651450.0,"Adam Feuerstein Tweets: At this point, $ICPT is probably asking the sell side to STOP defending them. It's only making the situation worse.",2017-09-21 14:36:00-04:00,ICPT,negative
651451.0,Adam Feuerstein Tweets: $ICPT — Leerink notes FDA hasn't tagged Ocaliva with a black box — yet — but don't be surprised if it happens.,2017-09-21 12:11:00-04:00,ICPT,negative
651452.0,Intercept Pharma Shares Up $4+ From Session Lows; Hearing Jefferies Issued Mid-Day Commentary Defending Stock,2017-09-21 11:16:00-04:00,ICPT,positive
651453.0,"Intercept Pharma Shares Down 3.5% From Session Highs As Traders, Over Last Few Mins., Circulate Chatroom Chatter FDA Sent Warning Letter Related To Liver Treatment",2017-09-21 10:55:00-04:00,ICPT,negative
651454.0,"Jim Cramer Advises His Viewers On STMicroelectronics, Altria Group And More",2017-09-21 08:53:00-04:00,ICPT,neutral
651455.0,18 Biggest Mid-Day Gainers For Friday,2017-09-15 12:21:00-04:00,ICPT,neutral
651456.0,"Benzinga's Top Upgrades, Downgrades For September 15, 2017",2017-09-15 09:29:00-04:00,ICPT,positive
651457.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,ICPT,neutral
651458.0,RBC Initiates Coverage on 6 Pharma Stocks After Hours,2017-09-14 16:47:00-04:00,ICPT,neutral
651459.0,10 Biggest Mid-Day Losers For Thursday,2017-09-12 13:08:00-04:00,ICPT,negative
651460.0,Did Improper Practices Affect Growth Trends For Intercept Pharma's Drugs?,2017-09-12 12:05:00-04:00,ICPT,positive
651461.0,UPDATE: Cantor Analyst On Intercept Says '...recent growth trends of the drug could have been affected by these improper practices with yet unquantifiable impact on future sales',2017-09-12 10:15:00-04:00,ICPT,positive
651462.0,UPDATE: Cantor Says Events Raised In Intercept's Letter 'signal a potential hurdle for further penetration and/or adoption of the treatment',2017-09-12 10:12:00-04:00,ICPT,neutral
651463.0,"Cantor Fitzgerald Issues Mid-Day Note On Intercept Pharma, Says Co.'s 'Dear Health Care Provider' Letter Raises Caution On PBC Franchise's Future Growth Potential In More Severe Patients",2017-09-12 10:08:00-04:00,ICPT,positive
651464.0,"Some Traders Attributing Move Lower In Intercept Pharma To Doc From Co.'s Chief Medical Officer To Health Care Providers Highlighting Seemingly Negative Postmarketing Cases For Its OCALIVA; However, Doc Is Dated Sept. 8, 2017",2017-09-12 09:14:00-04:00,ICPT,negative
651465.0,"Morgan Stanley Healthcare Conference Continues Today, Presenters Include: Innoviva, Seattle Genetics, Lab Corp, Anthem, Juno Therapeutics, and Intercept Pharmaceuticals",2017-09-12 08:58:00-04:00,ICPT,neutral
651466.0,BZ NOTE On Downside In Intercept Pharma Shares: Exec From Co. Will Be Speaking At Morgan Stanley's Healthcare Conference At 11:45 a.m. EDT,2017-09-12 08:20:00-04:00,ICPT,positive
651467.0,Intercept Pharma Shares Indicated Down ~12% Premarket On No News,2017-09-12 08:14:00-04:00,ICPT,neutral
651468.0,"Intercept Pharma Shares Bounce ~4% Off Session Lows; Stock Down Nearly 20% Since Jul. 28, Has High Short Interest At ~30%; Not Seeing Any News Thurs.",2017-08-03 10:49:00-04:00,ICPT,positive
651469.0,Intercept Pharma Spikes to High of $109.50 on Volume,2017-08-03 10:44:00-04:00,ICPT,neutral
651470.0,"Intercept Pharma Analysts See Growth Ahead, But Keep Underweight Rating For Now",2017-07-31 15:22:00-04:00,ICPT,positive
651471.0,15 Biggest Mid-Day Losers For Monday,2017-07-31 12:52:00-04:00,ICPT,negative
651472.0,Mid-Morning Market Update: Markets Mostly Higher; Discovery Communications To Acquire Scripps Networks Interactive,2017-07-31 10:21:00-04:00,ICPT,neutral
651473.0,Intercept Pharmaceuticals Announces The CONTROL Trial Met primary Objective By Showing Newly Started Treatment With atrovastatin Rapidly Reversed OCA-Associated Increases In LDL To Below Baseline Levels,2017-07-31 07:10:00-04:00,ICPT,neutral
651474.0,Intercept Reports Phase 2 AESOP OCA Met PRimary Endpoint Of ALP Reduction At 24 Weeks,2017-07-31 07:08:00-04:00,ICPT,neutral
651475.0,"Intercept Pharma Q2 EPS $(3.46) vs $(3.64) Est., Sales $30.89M vs $27.49M Est.",2017-07-31 07:06:00-04:00,ICPT,neutral
651476.0,"Intercept Pharma Shares Up 4.1% Following Jefferies Initiation With Buy Rating, $275 Price Target",2017-07-11 11:39:00-04:00,ICPT,positive
651477.0,"Jefferies Initiates Coverage On Intercept Pharmaceuticals with Buy Rating, Announces $275.00 Price Target",2017-07-11 07:39:00-04:00,ICPT,neutral
651478.0,"Companies Holding Shareholder Meetings Today Include Autohome, Gamestop, Mastercard, Kyocera, Intercept Pharma, PNC Financial, pSivida, ReWalk Robotics, RH, SITO Mobile, and Synergy Pharmaceuticals",2017-06-27 09:17:00-04:00,ICPT,neutral
651479.0,Intercept Gives Update on Data from FLINT Trial,2017-06-12 07:16:00-04:00,ICPT,neutral
651480.0,Intercept Pharma Reports Health Canada Has Granted Approval for Ocaliva for Treatment of PBC,2017-05-25 16:11:00-04:00,ICPT,positive
651481.0,"Intercept Pharma Earlier Reported Q1 EPS $(3.61) vs $(4.25) Est, Sales $21.05M vs $15.80M Est",2017-05-04 09:53:00-04:00,ICPT,neutral
651482.0,TheStreet's Adam Feuerstein Tweets '$ICPT completed enrollment in the interim analysis cohort of the OCA ph3 NASH trial. Data 1H 2019.',2017-05-04 07:11:00-04:00,ICPT,neutral
651483.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-04-04 08:16:00-04:00,ICPT,neutral
651484.0,"NICE Recommends Ocaliva  for the Treatment of Patients with Primary Biliary Cholangitis in England, Wales and Northern Ireland -",2017-03-02 04:46:00-05:00,ICPT,positive
651485.0,"Intercept Pharmaceuticals Reports Q4 EPS $(4.84) vs. $(3.74) Est., Sales $13.8M vs. $8.96M Est.",2017-02-23 07:06:00-05:00,ICPT,neutral
651486.0,Analysts Split On How To Read Intercept Switching Clinical Trial Endpoints,2017-02-13 11:47:00-05:00,ICPT,neutral
651487.0,What's With Wall Street's Lofty Price Targets On Intercept?,2017-02-10 14:57:00-05:00,ICPT,neutral
651488.0,"Cantor Fitzgerald In Midday Note Out Negative On Intercept, Maintains Underweight Rating Seeing No Change To Probability Of Success For Lead Candidate OCA In Current Phase 3 Trial",2017-02-10 12:34:00-05:00,ICPT,negative
651489.0,Here's Why Shares Of Intercept Jumped Nearly 10% On Friday,2017-02-10 09:47:00-05:00,ICPT,positive
651490.0,30 Stocks Moving In Friday's Pre-Market Session,2017-02-10 08:39:00-05:00,ICPT,neutral
651491.0,Adam Feuerstein Tweets: $ICPT says all changes to OCA ph3 study design accelerate enrollment/time to data and make positive results more likely.,2017-02-10 08:39:00-05:00,ICPT,positive
651492.0,UPDATE: Intercept Primary Endpoint Amended For Phase 3 REGENERATE Trial,2017-02-10 08:38:00-05:00,ICPT,neutral
651493.0,Intercept Spikes to Premarket High of $123,2017-02-10 08:37:00-05:00,ICPT,neutral
651494.0,"Intercept Shares Spike To High Of $123, Now Trading At $118",2017-02-10 08:37:00-05:00,ICPT,positive
651495.0,Adam Feuerstein Tweets: $ICPT amending ph3 study of OCA in NASH.,2017-02-10 08:36:00-05:00,ICPT,neutral
651496.0,"Intercept Shares Down Premarket, As Company Will Give An Update On Phase 3 REGENERATE Trial Obeticholic Acid For NASH Patients With Liver Firosis At 8:30am ET",2017-02-10 08:31:00-05:00,ICPT,positive
651497.0,Your Guide To 2017's Emerging Pharmaceuticals Catalysts,2017-02-07 14:39:00-05:00,ICPT,neutral
651498.0,Carmignac Gestion Reports 8.2% Stake In Intercept Pharmaceutical,2017-02-07 08:17:00-05:00,ICPT,neutral
651499.0,Hearing Takeover Chatter In Intercept,2017-01-27 13:33:00-05:00,ICPT,neutral
651500.0,15 Biggest Mid-Day Losers For Friday,2017-01-20 13:01:00-05:00,ICPT,negative
651501.0,"Benzinga's Top Upgrades, Downgrades For January 20, 2017",2017-01-20 09:18:00-05:00,ICPT,positive
651502.0,Needham Downgrades Intercept Pharmaceuticals To Hold,2017-01-20 08:02:00-05:00,ICPT,neutral
651503.0,Jefferies' Picks For 2017's Most And Least Likely Biotech M&A Targets,2017-01-05 16:10:00-05:00,ICPT,neutral
651504.0,13 Emerging Biotechs With Catalysts In 2017,2017-01-03 14:22:00-05:00,ICPT,neutral
651505.0,Why Companies File SEC CTO Requests,2016-12-29 13:32:00-05:00,ICPT,neutral
651506.0,Wall Street's M&A Chatter From December 28,2016-12-29 07:04:00-05:00,ICPT,neutral
651507.0,Intercept Shares Higher After It Requests To Keep Piece Of Q3 Info Secret Until 2020,2016-12-28 12:50:00-05:00,ICPT,positive
651508.0,Intercept Pharmaceuticals On Buyout Chatter Related To Recent Filing Of Confidential Treatment Order Tells Benzinga It Does Not Comment On M&A Speculation,2016-12-28 11:37:00-05:00,ICPT,neutral
651509.0,"Intercept Pharma Shares Spike to Session Highs, Quickly Give Back Gains from Last Few Mins as Traders Show Skepticism on Unconfirmed Takeover Chatter Being Passed Around",2016-12-28 11:26:00-05:00,ICPT,positive
651510.0,Intercept Spikes to High of $112 .90 on Volume,2016-12-28 11:23:00-05:00,ICPT,neutral
651512.0,Shares of Intercept Pharmaceuticals Up 4% At $108.06/Share,2016-12-28 11:09:00-05:00,ICPT,positive
651513.0,"BMO Capital Healthcare Conf. Takes Place Today; Presenters Include Neurocrine Biosciences, Ionis Pharmaceuticals, Horizon Pharma, And Intercept Pharmaceuticals",2016-12-14 08:41:00-05:00,ICPT,neutral
651514.0,Intercept Gets Marketing Authorization From the European Commission for Ocaliva,2016-12-14 07:04:00-05:00,ICPT,neutral
651515.0,"Traders Attributing Recent Spike Higher in Intercept Shares to Bloomberg Report Genefit is Exploring Options, Including a Possible Sale",2016-12-05 14:05:00-05:00,ICPT,positive
651516.0,Intercept Highlights Ocaliva Poster for AASLD: Presentations to 'explore changes in biochemical markers of disease progression in PBC patients with cirrhosis and renal impairment',2016-11-11 08:05:00-05:00,ICPT,neutral
651517.0,"Intercept Pharma Shares Edge Off Session Lows, Still Down 13% for Session; Hearing Baird Has Issued Mid-Day Defense on Name, Reiterated $332 Price Target",2016-11-03 13:05:00-04:00,ICPT,positive
651518.0,"Intercept Pharmaceuticals Reports Q3 EPS $(3.59) vs. Est. $(3.82), Rev. $5.1M vs. Est. $4.7M",2016-11-03 07:26:00-04:00,ICPT,neutral
651519.0,Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva for the Treatment of Primary Biliary Cholangitis in the European Union,2016-10-14 07:35:00-04:00,ICPT,positive
651520.0,EMA Issues Conditional Marketing Approval Recommendation for Intercept's Ocaliva for Treatment of Biliary Cirrhosis,2016-10-14 07:03:00-04:00,ICPT,positive
651521.0,Option Alert: ICPT Oct $165 Call Sweep; 537 @Ask @$2.20,2016-10-06 15:02:00-04:00,ICPT,positive
651522.0,NASH Sympathy Plays On Tobira Therapeutics Deal,2016-09-20 14:43:00-04:00,ICPT,positive
651523.0,"Conatus Pharma Shares Trading Up 27% on the Heels of Deal for Tobira Therapeutics; Also Watching Galmed Pharma, Galectin Therapeutics, Enanta Pharma, Intercept",2016-09-20 10:58:00-04:00,ICPT,positive
651524.0,Intercept Pharma Files NDA to Health Canada for Obeticholic Acid,2016-09-19 07:01:00-04:00,ICPT,neutral
651525.0,Intercept Announces Final Approval of Settlement of Class Action Litigation; Intercept to Pay $55M -8-K,2016-09-12 06:19:00-04:00,ICPT,positive
651526.0,Thursday Morning's Top Earnings Reports,2016-08-04 09:56:00-04:00,ICPT,positive
651527.0,"Intercept Pharmaceuticals Reports Q2 EPS $(3.14) vs. Est. $(3.70), Rev. $5.5M vs. Est. $1.46M",2016-08-04 07:45:00-04:00,ICPT,neutral
651528.0,Intercept Shares Turn Negative Following Mid-Day Sell Rating From Cantor,2016-07-06 15:57:00-04:00,ICPT,negative
651529.0,"Intercept Shares Falling as Hearing Cantor Fitzgerald Issued Mid-Day New Sell Rating, $58 Price Target on Stock",2016-07-06 13:59:00-04:00,ICPT,positive
651530.0,10 Biggest Mid-Day Losers For Thursday,2016-06-30 13:10:00-04:00,ICPT,negative
651531.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-06-30 08:23:00-04:00,ICPT,neutral
651532.0,Intercept Pharmaceuticals Announces Public Offering of Convertible Senior Notes,2016-06-29 16:19:00-04:00,ICPT,neutral
651533.0,Intercept Pharmaceuticals Finds Resistance,2016-06-28 15:34:00-04:00,ICPT,neutral
651534.0,"Intercept Pharmaceuticals Set To Rebound, Vetr Crowd Says",2016-06-17 14:49:00-04:00,ICPT,neutral
651535.0,Here's Why Barclays Is Bullish On Intercept Pharma,2016-06-01 08:54:00-04:00,ICPT,neutral
651536.0,Credit Suisse Reiterates Intercept's Lofty $200 Price Target; Ocaliva Will Be A 'Surprisingly Solid Launch',2016-05-31 15:37:00-04:00,ICPT,positive
651537.0,Credit Suisse On Intercept Pharma: 'We don't expect much competition for patients from ongoing placebo controlled COBALT trial',2016-05-31 13:58:00-04:00,ICPT,positive
651538.0,Cowen Lifts Intercept's Price Target To $215 Following Ocaliva Approval,2016-05-31 13:24:00-04:00,ICPT,positive
651539.0,Wild Ride For Intercept Pharmaceutical Investors,2016-05-31 12:14:00-04:00,ICPT,neutral
651540.0,Today's Top 10 Pre-Market Gainers,2016-05-31 09:28:00-04:00,ICPT,positive
651541.0,3 Reasons Goldman Sachs Still Neutral On Intercept Pharma,2016-05-31 08:30:00-04:00,ICPT,neutral
651542.0,10 Stocks Moving In Tuesday's Pre-Market Session,2016-05-31 08:21:00-04:00,ICPT,neutral
651543.0,"Intercept's Ocaliva To Experience 'Sluggish Uptake,' Investment Thesis Now 'Rapidly Shifts' To Execution In PBC",2016-05-31 07:49:00-04:00,ICPT,negative
651544.0,Intercept +13.5% Premarket @$161.03; FCC Granted Accelerated Approval to  Ocaliva for Treatment of Patients with PBC,2016-05-31 06:50:00-04:00,ICPT,positive
651545.0,Intercept Pharmaceuticals Announced FDA Grants Accelerated Approval to Ocaliva for the Treatment of Patients with PBC,2016-05-29 06:54:00-04:00,ICPT,positive
651546.0,"Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016, May 21-24",2016-05-18 11:02:00-04:00,ICPT,neutral
651547.0,"Intercept Pharma Reports Q1 EPS $(5.17) vs $(3.60) Est., Licensing Sales $445K vs $860K Est.",2016-05-05 17:23:00-04:00,ICPT,neutral
651548.0,"UPDATE: Lawsuit Claimed Intercept and Certain Officers Made Material Misrepresentations, Omissions Regarding Early Stopping of Phase 2b FLINT Trial of Obeticholic Acid in NASH",2016-05-03 06:40:00-04:00,ICPT,negative
651549.0,Intercept Pharmaceuticals Announces Agreement With Lead Plaintiff to Seek Court Approval of Proposed Resolution of Pending Class Action Litigation,2016-05-03 06:37:00-04:00,ICPT,positive
651550.0,Another Wild Ride In Intercept Pharmaceuticals,2016-04-08 13:26:00-04:00,ICPT,neutral
651551.0,"Morgan Stanley Downgrades Intercept Shares To Underweight, Cuts Target To $80",2016-04-08 09:01:00-04:00,ICPT,neutral
651552.0,10 Stocks Moving In Friday's Pre-Market Session,2016-04-08 08:32:00-04:00,ICPT,neutral
651553.0,"Intercept Jumps 5%, Confirms FDA's Unanimous Decision To Recommend Accelerated Ocaliva Approval",2016-04-08 07:29:00-04:00,ICPT,positive
651554.0,"Morgan Stanley Downgrades Intercept Pharmaceuticals to Underperform, Lowers PT to $80.00",2016-04-08 06:46:00-04:00,ICPT,negative
651555.0,"Intercept Resume Trade,  Shares Falling To $180/Share",2016-04-07 17:30:00-04:00,ICPT,positive
651556.0,Shares of Intercept Pharma to Resume Trade at 5:30 p.m. EDT,2016-04-07 17:16:00-04:00,ICPT,positive
651557.0,Intercept to Resume Trading at 5:30 PM ET,2016-04-07 17:07:00-04:00,ICPT,neutral
651558.0,"Intercept Publishes FDA Unanimous Decision Of Accelerated Approval Of Ocaliva For PBC Treatment, PDUFA is May 29th, 2016",2016-04-07 17:01:00-04:00,ICPT,positive
651559.0,"FDA Unanimous Vote Sees Substantial Evidence To Support Accelerated Approval Of Intercept's Liver Drug,  Vote Was 17-0",2016-04-07 15:50:00-04:00,ICPT,positive
651560.0,The Street's Adam Feuerstein Tweets: FDA webcast of the $ICPT went dark.,2016-04-07 14:48:00-04:00,ICPT,neutral
651561.0,The Street's Adam Feuerstein ‏Tweets: FDA biostat just showed K-M curves for OCA data in which agency's analysis is superior to $ICPT  Panel over. Positive vote coming.,2016-04-07 11:26:00-04:00,ICPT,positive
651562.0,"Many Sell Side Firm Notes In Recent Days Saying They Expect Intercept Pharma's OCA To Be Approved For PBC; Firms Include Leerink, Goldman, and Barclays, Among Others",2016-04-07 11:03:00-04:00,ICPT,positive
651563.0,"UPDATE: Intercept FDA Panel Begins 8am ET, AdComm To Discuss OCA For Use In PBC; Shares Up 5.6% Pre-Market",2016-04-07 07:57:00-04:00,ICPT,positive
651564.0,"Intercept Pharma. Shares Halted, Company Has AdComm For Obeticholic Acid (OCA) NDA For Treatment Of Progressive Liver Disease",2016-04-07 07:07:00-04:00,ICPT,positive
651565.0,Intercept Pharma Shares Halted News Pending,2016-04-07 07:05:00-04:00,ICPT,positive
651566.0,BMO Capital Initiates Coverage on Intercept Pharmaceuticals at Outperform,2016-04-07 06:29:00-04:00,ICPT,neutral
651567.0,Mid-Afternoon Market Update: Dow Falls Over 100 Points; Valeant Pharmaceuticals Shares Spike Higher,2016-04-05 15:52:00-04:00,ICPT,positive
651568.0,Mid-Day Market Update: Intercept Pharmaceuticals Gains Following Release of FDA Advisory Committee Documents; Godaddy Shares Decline,2016-04-05 12:11:00-04:00,ICPT,positive
651569.0,Benzinga's Volume Movers,2016-04-05 10:23:00-04:00,ICPT,neutral
651570.0,Mid-Morning Market Update: Markets Open Lower; Walgreens Earnings Top Views,2016-04-05 10:10:00-04:00,ICPT,negative
651571.0,Benzinga's Top Upgrades,2016-04-05 10:07:00-04:00,ICPT,positive
651572.0,Intercept Pharma Investors Cheering FDA Briefing Doc Release,2016-04-05 10:03:00-04:00,ICPT,positive
651573.0,"Intercept Shares Spike ~$10 Over Last Few Mins, Now Up ~16%",2016-04-05 09:41:00-04:00,ICPT,positive
651574.0,Wells Fargo Upgrades Intercept Pharmaceuticals to Outperform,2016-04-05 08:54:00-04:00,ICPT,positive
651575.0,10 Stocks Moving In Tuesday's Pre-Market Session,2016-04-05 08:20:00-04:00,ICPT,neutral
651576.0,Intercept Shares Spike to $145 Premarket Following Release of FDA Advisory Committee Documents,2016-04-05 08:11:00-04:00,ICPT,positive
651577.0,Benzinga's Top Initiations,2016-03-30 09:14:00-04:00,ICPT,positive
651578.0,"Credit Suisse Initiates Intercept With Outperform, $200 Target",2016-03-30 07:58:00-04:00,ICPT,positive
651579.0,"Goldman Sachs Initiates Coverage on Intercept Pharmaceuticals at Neutral, Announces $114.00 PT",2016-03-30 06:52:00-04:00,ICPT,neutral
651580.0,"Credit Suisse Initiates Coverage on Intercept Pharmaceuticals at Outperform, Announces $200.00 PT",2016-03-30 05:59:00-04:00,ICPT,positive
651581.0,Intercept Shares Move to High; Hearing Unconfirmed Market Chatter of Offer from AstraZeneca,2016-03-18 11:18:00-04:00,ICPT,positive
651582.0,Intercept to Study Role of Gut Microbiota in Treatment of Non-Viral Liver Diseases by Obeticholic Acid,2016-03-16 07:03:00-04:00,ICPT,neutral
651583.0,Intercept Pharmaceuticals to Study the Role of Gut Microbiota in the Treatment of Non-Viral Liver Diseases by Obeticholic Acid,2016-03-16 07:01:00-04:00,ICPT,neutral
651584.0,Roth's Piros: Galectin Therapeutics Shares Can Quadruple In Next 12 Months,2016-03-09 15:00:00-05:00,ICPT,positive
651585.0,"Barclays Maintains Overweight on Intercept Pharmaceuticals, Lowers PT to $200.00",2016-02-24 05:26:00-05:00,ICPT,negative
651586.0,Intercept Pharma. Reports Q4 EPS $(3.62) vs. Est. $(3.15),2016-02-23 07:14:00-05:00,ICPT,neutral
651587.0,"Keep An Eye On These 7 Stocks For February 16, 2016",2016-02-16 04:22:00-05:00,ICPT,neutral
651588.0,Benzinga's Weekend M&A Chatter,2016-02-15 19:35:00-05:00,ICPT,neutral
651589.0,"UPDATE: Oppenheimer Says Gilead Or Shire As Buyers Of ICPT Less Likely Than Merck, Abbvie, BMY, Pfizer, AstraZeneca and Roche",2016-02-12 14:08:00-05:00,ICPT,neutral
651590.0,"Oppenheimer Positive On ICPT, Says 'if the biotech gods have even a minor appreciation for irony, ICPT will be acquire'",2016-02-12 14:06:00-05:00,ICPT,positive
651591.0,RBC Capital 'fundamentally' Thinks No Deal Could Be In The Near Term For Intercept Pharma,2016-02-12 13:56:00-05:00,ICPT,negative
651592.0,Intercept Pharmaceuticals Soars 30%; Reuters Reported Company Exploring A Potential Sale,2016-02-12 13:43:00-05:00,ICPT,neutral
651593.0,Hearing Wells Fargo Out Negative on Prospects for Intercept Deal Prior to Apr 7 FDA Meeting,2016-02-12 13:27:00-05:00,ICPT,negative
651594.0,UPDATE: Intercept Said to be Working With Bankers on Potential Sale,2016-02-12 12:29:00-05:00,ICPT,neutral
651595.0,Intercept Halted on C/B,2016-02-12 12:19:00-05:00,ICPT,neutral
651596.0,-Intercept Pharmaceuticals Explores Following Receipt of Interest From Other Companies -Reuters,2016-02-12 12:18:00-05:00,ICPT,positive
651597.0,CentreView Partners Said to be Advising on Sale of Intercept to Astrazeneca,2016-02-09 09:47:00-05:00,ICPT,neutral
651598.0,"Hearing Intercept Pharma hires JPM to Handle Interest from Pfizer, Gilead, BristolMyers -Daily Mail",2016-02-02 09:43:00-05:00,ICPT,positive
651599.0,"Intercept Pharma. 8-K Shows CFO Barbara Duncan To Leave Company, Will Begin Search For Successor",2016-01-29 11:14:00-05:00,ICPT,positive
651600.0,Benzinga's Top Upgrades,2016-01-29 09:14:00-05:00,ICPT,positive
651601.0,"Morgan Stanley Upgrades Intercept Pharma, Maintains $100 Target",2016-01-29 08:56:00-05:00,ICPT,neutral
651602.0,"Morgan Stanley Upgrades Intercept Pharmaceuticals to Equalweight, Maintains $100.00 PT",2016-01-29 04:30:00-05:00,ICPT,neutral
651603.0,"Morgan Stanley Upgrades Intercept Pharmaceuticals to Equalweight, Maintains $100.00 PT",2016-01-29 04:30:00-05:00,ICPT,neutral
651604.0,Ameriprise Financial Reports 11.77% Passive Stake In Intercept Pharmaceuticals,2016-01-11 13:28:00-05:00,ICPT,positive
651605.0,Every Biotech Catalyst Wedbush Is Watching In 2016,2016-01-02 20:20:00-05:00,ICPT,neutral
651606.0,"UPDATE: Intercept Pharma Shares Jump 4.3+% Midday, Now In Positive Territory at ~$162.80",2015-12-21 13:17:00-05:00,ICPT,positive
651607.0,Intercept Spikes Higher,2015-12-21 13:14:00-05:00,ICPT,neutral
651608.0,Intercept Pharma Shares Trading Down ~8% Following News Late Thurs. Afternoon the FDA Has Extended the Date for Panel Review for Co.'s Treatment of PBC,2015-12-18 07:59:00-05:00,ICPT,positive
651609.0,Mid-Afternoon Market Update: Dow Surges Over 200 Points; Intercept Pharma Shares Climb On Takeover Rumor,2015-12-15 15:00:00-05:00,ICPT,positive
651610.0,Intercept Pharma Higher On Takeover Rumor,2015-12-15 14:08:00-05:00,ICPT,neutral
651611.0,Mid-Day Market Update: Kennametal Drops On Lowered Guidance; Lumber Liquidators Shares Jump,2015-12-15 13:30:00-05:00,ICPT,positive
651612.0,Mid-Morning Market Update: Markets Open Higher; FactSet Misses Q1 Views,2015-12-15 10:04:00-05:00,ICPT,negative
651613.0,Intercept +9.5% Premarket @$152.99; 'This is Money' Reported Monday that Shire Could be a Bidder for the Co,2015-12-15 08:31:00-05:00,ICPT,neutral
651614.0,Wedbush Offers Probabilities For Upcoming Catalysts In Emerging Pharmas,2015-12-08 08:29:00-05:00,ICPT,neutral
651615.0,"Wedbush's Moussatos Offers Probabilities for Upcoming Catalysts in Emerging Pharma Sector Heading Into '16: Discusses 14 Cos., Including BioMarin, Intercept, Regulus, Relypsa, Vitae, Xoma",2015-12-07 13:07:00-05:00,ICPT,neutral
651616.0,"Intercept Reports Initiation of Prospective Trial to Explore Effect of Combined OCA, Statin Therapy on Lipid Metabolism in NASH Patients",2015-12-07 07:05:00-05:00,ICPT,neutral
651617.0,Wells Fargo Initiates Coverage on Intercept Pharmaceuticals at Market Perform,2015-12-04 07:53:00-05:00,ICPT,positive
651618.0,"Intercept Pharmaceuticals Begins Phase 1 Study of INT-767, a Dual FXR and TGR5 Agonist",2015-11-30 16:05:00-05:00,ICPT,neutral
651619.0,Intercept Presents New Data Analyses on Non-Invasive Liver Testing From FLINT Trial of Obeticholic Acid in Nonalcoholic Steatohepatitis at AASLD 2015,2015-11-15 09:59:00-05:00,ICPT,neutral
651620.0,Intercept Presents New Primary Biliary Cholangitis Data at AASLD 2015,2015-11-15 09:57:00-05:00,ICPT,neutral
651621.0,"Benzinga's M&A Chatter for Tuesday November 10, 2015",2015-11-10 20:19:00-05:00,ICPT,neutral
651622.0,Strength in Intercept May be Attributed to Morgan Stanley Note Mentioning It as Potential Takeover Target for Amgen,2015-11-10 11:53:00-05:00,ICPT,positive
651623.0,Intercept Phamraceuticals Spiking Higher,2015-11-10 10:54:00-05:00,ICPT,neutral
651624.0,"Intercept Phamraceuticals Reports Q3 EPS $(2.10) vs. Est. $(2.74), Rev. $445K vs. Est. $420K",2015-11-09 07:06:00-05:00,ICPT,neutral
651625.0,"Morgan Stanley Sees 33% Downside At Intercept Pharma, Increased Risk",2015-10-29 09:54:00-04:00,ICPT,negative
651626.0,Intercept Pharmaceuticals Rebounds After Phase 2 Trial Of OCA Disappoints,2015-10-28 16:15:00-04:00,ICPT,negative
651627.0,Mid-Morning Market Update: Markets Open Higher; Hershey Earnings Beat Views,2015-10-28 10:13:00-04:00,ICPT,neutral
651628.0,Morning Market Losers,2015-10-28 09:57:00-04:00,ICPT,negative
651629.0,Intercept Pharmaceuticals Announces Results Of Phase 2 Trial Of OCA In Nash Patients In Japan;  Says 40MG OCA Dose Group Achieved Statistical Significance On The Primary Endpoint vs Placebo,2015-10-28 07:33:00-04:00,ICPT,positive
651630.0,Intercept Pharma Reports Initiation of REGENERATE Trial for Obeticholic Acid in NASH Patients with Advanced Liver Fibrosis,2015-09-28 07:05:00-04:00,ICPT,positive
651631.0,Mid-Morning Market Update: Markets Open Lower; Carlyle Group To Acquire Blyth For $6/Share,2015-08-31 10:22:00-04:00,ICPT,negative
651632.0,Morning Market Gainers,2015-08-31 09:45:00-04:00,ICPT,neutral
651633.0,Intercept +4.5% Premarket Following Announcement of FDA Priority Review for Obeticholic Acid for Treatment of Primary Biliary Cirrhosis,2015-08-31 08:24:00-04:00,ICPT,neutral
651634.0,FDA Grants Priority Review for Intercept's Obeticholic Acid for the Treatment of Primary Biliary Cirrhosis,2015-08-31 07:05:00-04:00,ICPT,positive
651635.0,Calls Of Note: Wall Street Research Moving The Market On Thursday,2015-08-13 13:35:00-04:00,ICPT,neutral
651636.0,Pipeline Updates Make These Three Biotech Stocks Worth Watching,2015-08-10 09:48:00-04:00,ICPT,positive
651637.0,Intercept Pharma Reports Q2 Loss of $1.99/Share,2015-08-05 16:25:00-04:00,ICPT,negative
651638.0,CNBC's Meg Tirrel Speculates About Gilead's New Acquisiton,2015-07-10 06:52:00-04:00,ICPT,neutral
651639.0,How Wedbush's Liana Moussatos Is Trading These Biopharma Stocks,2015-07-06 15:41:00-04:00,ICPT,neutral
651640.0,5 Biotech Stocks On Deck With The FDA,2015-06-30 13:39:00-04:00,ICPT,neutral
651641.0,Intercept Pharma Announces Submission of Applicaation in US and Europe to Market Biliary Cirrhosis Treatment,2015-06-29 16:06:00-04:00,ICPT,neutral
651642.0,"Sportsman's Warehouse, Bob Evans, Peabody Energy Lead Tuesday's After-Hours Movers",2015-06-16 17:52:00-04:00,ICPT,positive
651643.0,Benzinga's Top Initiations,2015-05-21 09:07:00-04:00,ICPT,positive
651644.0,4 SMID-Cap Biotechs Barclays Just Confessed It Loves,2015-05-21 09:00:00-04:00,ICPT,positive
651645.0,Barclays Initiates Intercept Pharmaceuticals With Overweight,2015-05-21 08:24:00-04:00,ICPT,negative
651646.0,"Barclays Initiates Coverage on Intercept Pharmaceuticals at Overweight, Announces $425.00 PT",2015-05-21 04:12:00-04:00,ICPT,negative
651647.0,Intercept Pharmaceuticals Downgraded,2015-05-20 08:27:00-04:00,ICPT,neutral
651648.0,Bank of America Downgrades Intercept Pharmaceuticals to Neutral,2015-05-19 11:51:00-04:00,ICPT,neutral
651649.0,Intercept Pharmaceuticals Announces Plans for Pivotal Phase 3 Clinical Trial of Obeticholic Acid in NASH,2015-05-19 06:03:00-04:00,ICPT,neutral
651650.0,Will The Bulls In Options Continue To Be Disappointed This Week?,2015-05-18 14:17:00-04:00,ICPT,negative
651651.0,Intercept Pharmaceuticals Breaks Out,2015-05-13 10:56:00-04:00,ICPT,neutral
651652.0,"Analysts Positive On Intercept Pharmaceuticals After Earnings, Pipeline Update",2015-05-12 12:31:00-04:00,ICPT,positive
651653.0,Intercept Q1 EPS -$1.78 vs -$1.69 est,2015-05-11 06:03:00-04:00,ICPT,neutral
651654.0,Intercept Announces New FLINT Trial Data Showing OCA Treatment Increases Fibrosis Resolution and Cirrhosis Prevention in High-Risk NASH Patients,2015-04-23 04:23:00-04:00,ICPT,neutral
651655.0,"Intercept Pharma Shares Higher Following New Buy Rating, $465 Target From UBS",2015-04-17 10:20:00-04:00,ICPT,positive
651656.0,"UBS Initiates Coverage on Intercept Pharmaceuticals at Buy, Announces $465.00 PT",2015-04-17 07:14:00-04:00,ICPT,neutral
651657.0,Biotech Investors: Nomura Says To Watch These Dates,2015-04-10 13:10:00-04:00,ICPT,neutral
651658.0,Options Pro Says Intercept Shares Will Go 'Much Higher' Through The End Of The Year,2015-04-08 14:51:00-04:00,ICPT,positive
651659.0,Intercept Pharma Reports Proceeds From Public Offering Of $366.8M,2015-04-06 16:11:00-04:00,ICPT,neutral
651660.0,Wedbush Securities Believes Financing Further Extends Cash Runway For Intercept Pharmaceuticals,2015-04-01 09:56:00-04:00,ICPT,positive
651661.0,CNBC's Stock Pops & Drops From March 31,2015-04-01 06:59:00-04:00,ICPT,neutral
651662.0,8 Oppenheimer Analysts Choose Their Favorite Healthcare Stocks,2015-03-31 12:04:00-04:00,ICPT,positive
651663.0,Morning Market Losers,2015-03-31 09:51:00-04:00,ICPT,negative
651664.0,"Intercept Prices 1.2M Shares, Proceeds To Be ~$338.4M",2015-03-31 09:14:00-04:00,ICPT,positive
651665.0,Intercept Shares Fall 4% Premarket Following Announcement of 1.2M Share Secondary Offering,2015-03-31 08:11:00-04:00,ICPT,positive
651666.0,Intercept Pharmaceuticals Announces Proposed 1.2M Share Offering Of Common Stock,2015-03-31 06:25:00-04:00,ICPT,positive
651667.0,Intercept Pharma Prices 1.2M Shares of Common Stock,2015-03-31 06:25:00-04:00,ICPT,positive
651668.0,"Intercept Pharma Holder Orbimed Reports Stake Of 4.95%, Down From 5.64% On 03/25/2015",2015-03-30 16:14:00-04:00,ICPT,neutral
651669.0,"Intercept Pharmaceuticals Shareholder Orbimed Advisors Sells 157,200 Shares @$286.75/Share -Form 4",2015-03-30 16:02:00-04:00,ICPT,positive
651670.0,Genfit's Loss Is Gain For Intercept Pharmaceuticals,2015-03-27 13:06:00-04:00,ICPT,positive
651671.0,Intercept Pharmaceuticals Shares Rise ~4% Premarket as Deutsche Bank Raises PT from $300 to $400,2015-03-27 08:24:00-04:00,ICPT,positive
651672.0,Genfit Will Target High-Risk Patients In Phase 3 Trial,2015-03-26 15:14:00-04:00,ICPT,neutral
651673.0,Adam Feuerstein @adamfeuerstein Tweet: $GNFT is asked to disclose the the uncorrected results for the NASH resolution primary endpoint — and refuses. Game over.,2015-03-26 15:03:00-04:00,ICPT,neutral
651674.0,"Genfit States LDL Levels ""Significantly Decreased""; Positive Cardio-Metabolic Effects in GFT505",2015-03-26 14:48:00-04:00,ICPT,positive
651675.0,Genfit GFT505 Phase 3 Trial To Begin By Year End,2015-03-26 14:38:00-04:00,ICPT,neutral
651676.0,Genfit Conference Call Begins,2015-03-26 14:33:00-04:00,ICPT,neutral
651677.0,"UPDATE: Genfit Shows No Signs Of Cardiac Events, No Signal On Cancer",2015-03-26 12:56:00-04:00,ICPT,negative
651678.0,"Genfit Announces Topline Results From Golden-505 Trial In Nash; Gft505 Demonstrates Dose-Dependent Efficacy On Primary Endpoint, After Controlling For Baseline Severity And Heterogeneity",2015-03-26 12:54:00-04:00,ICPT,neutral
651680.0,Intercept Spikes Higher,2015-03-26 12:52:00-04:00,ICPT,neutral
651681.0,Intercept Pharma Holder Orbimed Cuts Stake From 6.56% To 5.64%,2015-03-25 16:53:00-04:00,ICPT,negative
651682.0,Why Intercept Might Be A Better Bet Than Biogen Right Now,2015-03-24 07:43:00-04:00,ICPT,positive
651683.0,"Janney Capital Maintains Buy on Intercept Pharmaceuticals, Raises PT to $350.00",2015-03-23 05:42:00-04:00,ICPT,neutral
651684.0,Morning Market Gainers,2015-03-20 09:37:00-04:00,ICPT,neutral
651685.0,Biotech Stocks Soar Amid Positive News,2015-03-20 08:54:00-04:00,ICPT,positive
651686.0,Benzinga's Top #PreMarket Gainers,2015-03-20 08:14:00-04:00,ICPT,positive
651687.0,US Stock Futures Signal Higher Start On Wall Street,2015-03-20 07:39:00-04:00,ICPT,neutral
651688.0,Intercept Shares at $300 Premarket on Positive Phase 2B Flint Trial Data,2015-03-20 06:36:00-04:00,ICPT,positive
651689.0,Intercept Announces Positive Data Analyses from FLINT Trial of Obeticholic Acid in NASH,2015-03-20 06:00:00-04:00,ICPT,positive
651690.0,Is Intercept The Next Biotech To Break Out?,2015-03-18 16:10:00-04:00,ICPT,neutral
651691.0,"Baird Maintains Outperform on Intercept Pharmaceuticals, Raises PT to $344.00",2015-03-18 05:58:00-04:00,ICPT,neutral
651692.0,Benzinga's Top Initiations,2015-03-17 08:55:00-04:00,ICPT,positive
651693.0,MLV & Co. Initiates Intercept Pharmaceuticals With Hold,2015-03-17 08:20:00-04:00,ICPT,neutral
651694.0,"MLV & Co. Initiates Coverage on Intercept Pharmaceuticals at Hold, Announces $273.00 PT",2015-03-17 07:18:00-04:00,ICPT,neutral
651695.0,Intercept Pharmaceuticals Revisits $300 For The First Time In 7 Months,2015-03-16 14:57:00-04:00,ICPT,neutral
651696.0,Will Intercept Pharma Outperform? These Analysts Think So,2015-03-05 23:40:00-05:00,ICPT,neutral
651697.0,US Judge Refuses to Dismiss Shareholder Lawsuit vs Intercept Pharmaceuticals Regarding Disclosures Relating to Fliny Trial,2015-03-04 15:47:00-05:00,ICPT,negative
651698.0,"Intercept Shares +5%; Hearing Data, Possibly Additional News Around March 20-22",2015-03-04 10:08:00-05:00,ICPT,positive
651699.0,Intercept Pharmaceuticals Reports Q4 Loss/Share $(1.63); May Not Compare With $0.06 EPS Est; Revenue $445K vs $430K Est,2015-03-02 06:03:00-05:00,ICPT,neutral
651700.0,"Earning & Economic Calendar for Monday March 2, 2015",2015-03-02 04:51:00-05:00,ICPT,neutral
651701.0,"Earnings Scheduled For March 2, 2015",2015-03-02 04:44:00-05:00,ICPT,neutral
651702.0,Hearing Unconfirmed Market ChatterEarly FDA Approval to be Announced for Intercept Nash Treatment; March 20-22,2015-02-27 09:55:00-05:00,ICPT,positive
651703.0,"Intercept to Report FY 2014 Financial Results on March 2, 2015",2015-02-23 06:05:00-05:00,ICPT,neutral
651704.0,Intercept Appoints Lisa Bright Chief Commercial & Corporate Affairs Officer,2015-02-19 16:50:00-05:00,ICPT,positive
651705.0,"Intercept Pharma Prices 1M Share Offering at $176/Share, Expecting Net Proceeds $166.2M",2015-02-04 19:37:00-05:00,ICPT,positive
651706.0,"Intercept Pharmaceuticals Announces 800,000 Share Proposed Public Offering of Common Stock",2015-02-03 16:29:00-05:00,ICPT,positive
651707.0,Cowen And Company Analyst Explains Why Intercept Pharmaceuticals Is 'Absolutely A Buy',2015-02-02 08:00:00-05:00,ICPT,neutral
651708.0,"Biotech Breakdown: Market Breaks...Gilead, Kite Pharma & Biogen Idec Worth Watching",2015-02-01 21:14:00-05:00,ICPT,positive
651709.0,"Cowen Analyst Likes Intercept Pharmaceuticals, ACADIA Pharmaceuticals And Raptor Pharmaceutical",2015-02-01 12:54:00-05:00,ICPT,positive
651710.0,Mid-Afternoon Market Update: Crude Oil Jumps 7.5%; Visa Shares Climb On Earnings Beat,2015-01-30 15:26:00-05:00,ICPT,negative
651711.0,"Intercept Pharmaceuticals Soars 20%, Possible Short Squeeze",2015-01-30 13:02:00-05:00,ICPT,neutral
651712.0,Mid-Day Market Update: Amazon Jumps On Upbeat Earnings; Hawaiian Holdings Shares Slide,2015-01-30 12:24:00-05:00,ICPT,positive
651713.0,Benzinga's Volume Movers,2015-01-30 10:44:00-05:00,ICPT,neutral
651714.0,Mid-Morning Market Update: Markets Drop; Mastercard Profit Tops Expectations,2015-01-30 10:42:00-05:00,ICPT,positive
651715.0,Morning Market Gainers,2015-01-30 09:51:00-05:00,ICPT,neutral
651716.0,"Friday Morning Movers: Amazon Pops, Deckers Outdoor Plummets Following Earnings Results",2015-01-30 09:27:00-05:00,ICPT,positive
651717.0,Benzinga's Top #PreMarket Gainers,2015-01-30 08:13:00-05:00,ICPT,positive
651718.0,Intercept Receives Breakthrough Therapy Designation from FDA for Obeticholic Acid for NASH With Liver Fibrosis,2015-01-29 16:08:00-05:00,ICPT,neutral
651719.0,Deutsche Bank: No Big Move In FY15 For Intercept Pharmaceuticals,2015-01-22 13:38:00-05:00,ICPT,negative
651720.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3,2015-01-13 10:58:00-05:00,ICPT,neutral
651721.0,"Bank of America Reinstates Buy on Intercept, Announces $188.00 PT",2014-12-15 06:56:00-05:00,ICPT,neutral
651722.0,Intercept Announces Publication Of Meta-Analysis From The Global PBC Study Group In Gastroenterology,2014-12-05 06:09:00-05:00,ICPT,neutral
651723.0,Intercept Announces Publication of Meta-Analysis From Global PBC Study Group in Gastroenterology,2014-12-05 06:04:00-05:00,ICPT,neutral
651724.0,Dan Rosenblum @sharkbiotech Tweet: $ICPT CEO more confident in OCA for NASH now then back in January when trial was,2014-12-02 13:15:00-05:00,ICPT,positive
651725.0,Intercept Pharmaceuticals Names Lisa Bright as Head of Europe,2014-11-17 06:07:00-05:00,ICPT,positive
651726.0,The Top 25 Analysts On Wall Street,2014-11-13 10:47:00-05:00,ICPT,positive
651727.0,Intercept Announces Additional Data for OCA in Primary Biliary Cirrhosis Presented at AASLD Annual Meeting,2014-11-08 18:28:00-05:00,ICPT,neutral
651728.0,Mid-Afternoon Market Update: Lions Gate Surges On Earnings Beat; Abercrombie & Fitch Shares Decline,2014-11-07 15:14:00-05:00,ICPT,positive
651729.0,4 Stocks Twitter Is Buzzing About,2014-11-07 14:03:00-05:00,ICPT,neutral
651730.0,"Midday Losers From November 7: Roka Bioscience, Salix Pharmaceuticals, Intercept Pharmaceuticals, Extended Stay America",2014-11-07 13:38:00-05:00,ICPT,negative
651731.0,"Leerink Swann Downgrades Intercept to Market Perform, Lowers PT to $191.00",2014-11-07 11:51:00-05:00,ICPT,negative
651732.0,Morning Market Losers ,2014-11-07 09:58:00-05:00,ICPT,negative
651733.0,"Intercept Shares Fall Almost 20% Premarket, as Lancet Report Cites Raised Bad Cholesterol Levels in Patients Receiving NASH Drug",2014-11-07 09:12:00-05:00,ICPT,negative
651734.0,Benzinga's Top #PreMarket Losers ,2014-11-07 08:22:00-05:00,ICPT,negative
651735.0,FLINT Trial in NASH Published in The Lancet,2014-11-06 19:40:00-05:00,ICPT,neutral
651736.0,Intercept Reports Q3 EPS of $(1.69) vs $(1.10) Est,2014-11-06 19:38:00-05:00,ICPT,neutral
651737.0,Meet The 5 Companies Loving Obamacare,2014-11-04 20:04:00-05:00,ICPT,positive
651738.0,"Intercept to Report Q3 2014 Results on November 7, 2014",2014-10-31 06:03:00-04:00,ICPT,neutral
651739.0,Morning Market Losers ,2014-10-08 09:48:00-04:00,ICPT,negative
651740.0,Benzinga's Top #PreMarket Losers,2014-10-08 08:09:00-04:00,ICPT,negative
651741.0,Intercept Data to be Presented at the 2014 AASLD Annual Meeting ,2014-10-08 06:33:00-04:00,ICPT,neutral
651742.0,Conatus Pharmaceuticals Shares Move Higher; May be Attributed to Seeking Alpha Post,2014-09-16 11:20:00-04:00,ICPT,positive
651743.0,Benzinga's Top Initiations,2014-09-05 09:00:00-04:00,ICPT,positive
651744.0,Cowen Initiates Intercept At Outperform,2014-09-05 07:23:00-04:00,ICPT,neutral
651745.0,"Cowen & Company Initiates Coverage on Intercept at Outperform, Announces $420.00 PT",2014-09-05 06:30:00-04:00,ICPT,neutral
651746.0,Cowen Starts Intercept Pharmaceuticals With Outperform; PT $420 -Reuters,2014-09-05 05:33:00-04:00,ICPT,neutral
651747.0,Intercept Spikes to Lows on Volume,2014-08-28 15:56:00-04:00,ICPT,negative
651748.0," Orbimed Advisors Sells 111,258 Shares of Intercept Pharmaceuticals @$298.06/Share -Form 4",2014-08-27 21:15:00-04:00,ICPT,positive
651749.0," Intercept Pharmaceuticals Shareholder Orbimed Advisors Sells 60,000 Shares @$299.82/Share -Form 4",2014-08-18 21:13:00-04:00,ICPT,positive
651750.0,Morning Market Losers ,2014-08-15 09:48:00-04:00,ICPT,negative
651751.0,Benzinga's Top #PreMarket Losers,2014-08-15 08:24:00-04:00,ICPT,negative
651752.0,"Shares of Intercept Moving Higher; Report of Tweet Mentioning Potential Deal by Gilead being Passed Around, Totally Unconfirmed",2014-08-14 14:34:00-04:00,ICPT,positive
651753.0,CNBC's Stock Pops & Drops From August 12,2014-08-13 07:04:00-04:00,ICPT,neutral
651754.0,Markets Marginally Lower In Quiet Trading Session,2014-08-12 16:40:00-04:00,ICPT,negative
651755.0,#Premarket Prep Technical Update - Intercept Pharmaceuticals Trading Higher But Well Off Highs For The Session,2014-08-12 15:39:00-04:00,ICPT,positive
651756.0,U.S. Job Openings Climb; Leerink Swann Bullish On Intercept Pharmaceuticals,2014-08-12 15:10:00-04:00,ICPT,neutral
651757.0,U.S. Stocks Fall; Dealertrack Shares Surge On Upbeat Results,2014-08-12 12:47:00-04:00,ICPT,positive
651758.0,Markets Mostly Flat; Flowers Foods Profit Misses Estimates,2014-08-12 11:26:00-04:00,ICPT,positive
651759.0,Benzinga's Volume Movers,2014-08-12 10:31:00-04:00,ICPT,neutral
651760.0,Morning Market Movers ,2014-08-12 09:42:00-04:00,ICPT,neutral
651761.0,Conatus Shares Move Higher On Industry Data,2014-08-12 09:11:00-04:00,ICPT,positive
651762.0,Benzinga's Top #PreMarket Gainers,2014-08-12 08:08:00-04:00,ICPT,positive
651763.0,"Leerink Swann Upgrades Intercept to Outperform, Raises PT to $445.00",2014-08-12 06:19:00-04:00,ICPT,neutral
651764.0,Intercept Pharmaceutical's Shares Soar On Earnings,2014-08-11 17:16:00-04:00,ICPT,positive
651765.0,"Intercept Pharma Shares Resume Trade, Now Up ~39%",2014-08-11 16:40:00-04:00,ICPT,positive
651766.0,PREVIEW: Intercept to Resume Trading at 4:40 PM ET,2014-08-11 16:20:00-04:00,ICPT,neutral
651767.0,Intercept Pharmaceuticals Says INT-767 Phase 1 Trial Initiation Expected in H1 2015,2014-08-11 16:18:00-04:00,ICPT,neutral
651768.0,Intercept Reports Q2 EPS of $1.51; Revenue of $445.0K vs $400.0K Est,2014-08-11 16:16:00-04:00,ICPT,neutral
651769.0,Intercept Pharma 10-Q Just Filed,2014-08-11 16:14:00-04:00,ICPT,neutral
651770.0,Intercept Pharma Halted News Pending,2014-08-11 16:00:00-04:00,ICPT,neutral
651771.0,"Adam Feuerstein Tweet: After spending time with $ICPT NASH study this week for Mailbag, $GALT NASH trial is farce by comparison.",2014-07-25 14:01:00-04:00,ICPT,negative
651772.0,Dow Sets New Intraday High; Citigroup Impresses With Earnings,2014-07-14 16:44:00-04:00,ICPT,positive
651773.0,Intercept Pharmaceutical Shares Up Amid Deutsche Bank Initiation,2014-07-14 11:51:00-04:00,ICPT,positive
651774.0,"Deutsche Bank Initiates Coverage on Intercept at Buy, Announces $395.00 PT",2014-07-14 06:25:00-04:00,ICPT,neutral
651775.0,Markets Little Changed Ahead Of 4th Of July Break,2014-07-02 16:34:00-04:00,ICPT,neutral
651776.0,Benzinga's Top Initiations,2014-07-02 07:43:00-04:00,ICPT,positive
651777.0,"Goldman Sachs Initiates Coverage on Intercept at Neutral, Announces $265.00 PT",2014-07-02 06:43:00-04:00,ICPT,neutral
651778.0,"RBC Capital Initiates Coverage on Intercept at Outperform, Announces $425.00 PT",2014-06-30 16:04:00-04:00,ICPT,neutral
651779.0,Markets Slightly Lower As Bullard Hints Higher Rates Could Come Sooner Than Expected,2014-06-26 16:34:00-04:00,ICPT,negative
651780.0,Analysts Comment On Intercept Pharmaceuticals Amid Share Decline Following FLINT Data Delay,2014-06-26 12:18:00-04:00,ICPT,neutral
651781.0,Hearing Summer Street Reiterates Buy and $650 PT on Intercept on Potential FDA Breakthrough Therapy Designation for NASH,2014-06-26 10:38:00-04:00,ICPT,neutral
651782.0,"Leerink Swann Initiates Coverage on Intercept at Market Perform, Announces $270.00 PT",2014-06-26 06:48:00-04:00,ICPT,neutral
651783.0,"Nomura Initiates Coverage on Intercept at Neutral, Announces $294.00 PT",2014-06-26 06:47:00-04:00,ICPT,neutral
651784.0,"Top Healthcare Movers For June 9, 2014",2014-06-09 14:27:00-04:00,ICPT,positive
651785.0,Market Wrap For May 29: Investors Welcome Another Record High For The S&P 500,2014-05-29 16:41:00-04:00,ICPT,positive
651786.0,Morning Market Movers ,2014-05-29 09:38:00-04:00,ICPT,neutral
651787.0,Benzinga's Top #PreMarket Gainers,2014-05-29 08:14:00-04:00,ICPT,positive
651788.0,"Shares of Intercept Pharma Spike Nearly $20 Following Fast Track News, Now Up ~7.7% in Post-Market Trade",2014-05-28 16:17:00-04:00,ICPT,positive
651789.0,UPDATE: Intercept Announces FDA Fast Track Designation to Obeticholic Acid for Treatment of Primary Biliary Cirrhosis,2014-05-28 16:16:00-04:00,ICPT,neutral
651790.0,Intercept Announces FDA Fast Track Designation to Obeticholic Acid for Treatment of Primary Biliary Cirrhosis,2014-05-28 16:16:00-04:00,ICPT,neutral
651791.0,Citi Analyst Defends Intercept Pharmaceuticals ,2014-05-28 14:26:00-04:00,ICPT,neutral
651792.0,"Investors in Intercept Pharma Cheer Co.'s Disclosure of Emails Related to FLINT Trial, Shares Up More Than 4% at Last Check",2014-05-22 10:38:00-04:00,ICPT,positive
651793.0,Intercept Shares Rebound 4% Premarket; May be Attributed to Oppenheimer Defense,2014-05-21 08:08:00-04:00,ICPT,positive
651794.0,"Market Wrap For May 20: Markets Sharply Lower On Fed Talk, Disappointing Earnings",2014-05-20 16:42:00-04:00,ICPT,negative
651795.0,Intercept Pharmaceuticals Tumbles On Safety Concern Allegations,2014-05-20 11:02:00-04:00,ICPT,positive
651796.0,Morning Market Losers ,2014-05-20 09:53:00-04:00,ICPT,negative
651797.0,Adam Feuerstein Tweet: 'SummerStreet defends $ICPT. Nothing to see here. reiterates $650 PT',2014-05-20 08:53:00-04:00,ICPT,neutral
651798.0,Benzinga's Top #PreMarket Losers,2014-05-20 08:24:00-04:00,ICPT,negative
651799.0,"Intercept Pharma Shares Plunge 14+% as TheStreet's Adam Feuerstein Reports 'Intercept Pharma, Government Scientists Spar Over Negative Safety of Liver Drug, Emails Show'",2014-05-20 07:35:00-04:00,ICPT,positive
651800.0,Intercept Shares Fall 15% Premarket,2014-05-20 07:35:00-04:00,ICPT,positive
651801.0,"Adam Feuerstein ‏Tweet: '$ICPT, Government Scientists, Spar Over Negative Safety of Liver Drug, Emails Show'",2014-05-20 07:34:00-04:00,ICPT,negative
651802.0,Late Afternoon Market Movers,2014-05-19 15:47:00-04:00,ICPT,neutral
651803.0,Market Wrap For May 15: Bears Return In Full-Force As Dow Suffers Triple-Digit Point Loss,2014-05-15 16:41:00-04:00,ICPT,negative
651804.0,"Summer Street Initiates Coverage on Intercept at Buy, Announces $650.00 PT",2014-05-15 09:46:00-04:00,ICPT,neutral
651805.0,Intercept Reports Q1 Revenue of $405.0K vs $400.0K Est,2014-05-07 17:00:00-04:00,ICPT,neutral
651806.0,Intercept Reports Additional Positive OCA Data in Patients With Bile Acid Diarrhea at Digestive Disease Week ,2014-05-06 16:11:00-04:00,ICPT,positive
651807.0,"Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings",2014-04-14 16:36:00-04:00,ICPT,positive
651808.0,Intercept Announces Additional Positive Data from POISE Trial at EASL,2014-04-12 14:06:00-04:00,ICPT,positive
651809.0,Intercept Issues Preclinical Data Showing OCA's Potential Role in Preventing Complications of Cirrhosis,2014-04-11 09:03:00-04:00,ICPT,neutral
651810.0,"Jon Gardner tweets: 'Just spoke with $ICPT CEO Pruzanski, who says the company has not hired Rachel ""$800 Price Target"" McMinn. #ILC2014'",2014-04-10 11:18:00-04:00,ICPT,neutral
651811.0,"Intercept Will Not Need Partner for Phase 3 NASH Trial, Co. Share Sale Will Fund Trial, Launch for PBC - Bloomberg",2014-04-10 09:07:00-04:00,ICPT,positive
651812.0,"Market Wrap For April 4: Dow Suffers Triple Digit Point Loss, Nasdaq Continues To Underperform",2014-04-04 16:44:00-04:00,ICPT,negative
651813.0,Data From Intercept's Pivotal Phase 3 POISE Trial of Its FXR Agonist Obeticholic Acid to Treat Primary Biliary Cirrhosis and Other Key Obeticholic Acid Data to be Presented at EASL 2014 ,2014-04-04 10:12:00-04:00,ICPT,positive
651814.0,Intercept Announces Will Present Data from PIVOTAL Phase 3 POISE Trial of FXR Agonist Obeticholic Acid at EASL 2014 Apr. 9-13th,2014-04-04 10:10:00-04:00,ICPT,neutral
651815.0,US Stock Futures Nudge Higher Ahead Of Jobs Data,2014-04-04 07:27:00-04:00,ICPT,neutral
651816.0,UPDATE: Intercept Shares Rise More than 1% Premarket Following Announcement of Pricing of 1M Share Offering at $320/Share,2014-04-04 07:18:00-04:00,ICPT,positive
651817.0,Intercept Pharmaceuticals Prices 1M Share Offering at $320.00/Share,2014-04-04 05:40:00-04:00,ICPT,positive
651818.0,"Amended 13G Filing from SAC Capital on Intercept Pharma Shows Less Than 0.1% Stake, Had Shown 6.4% Stake as of Dec. 31st",2014-04-03 16:10:00-04:00,ICPT,neutral
651819.0,"Intercept Pharma Reports Proposed Offering for 1M Shares, 400K Through Selling Holders, 600K by the Co.",2014-04-01 17:40:00-04:00,ICPT,positive
651820.0,Market Wrap For March 17: Investors Focused On Economic Data Instead Of Crimea Concerns,2014-03-17 16:45:00-04:00,ICPT,positive
651821.0,Intercept Pharmaceuticals Announces Q4 Earnings,2014-03-17 16:32:00-04:00,ICPT,neutral
651822.0,Intercept Pharmaceuticals Trading Sharply Lower,2014-03-17 14:30:00-04:00,ICPT,negative
651823.0,Needham Lifts Target on Intercept Pharma from $320 to $500,2014-03-17 14:05:00-04:00,ICPT,neutral
651824.0,Shares of Intercept Pharma Moving Lower as Hearing Oppenheimer Analyst Has Said Expecting an Equity Offering Soon,2014-03-17 13:34:00-04:00,ICPT,neutral
651825.0,Hearing Oppenheimer Says Intercept Likely to do Secondary Offering,2014-03-17 13:30:00-04:00,ICPT,neutral
651826.0,Top Trending Tickers On StockTwits For March 17,2014-03-17 09:38:00-04:00,ICPT,positive
651827.0,"From Intercept Call: Noting Serious Adverse Events Were Split Between Groups, One Event Was in Placebo, Other Was in Drug Group",2014-03-17 08:46:00-04:00,ICPT,negative
651828.0,Benzinga's Top #PreMarket Losers,2014-03-17 08:20:00-04:00,ICPT,negative
651829.0,Intercept Announces Phase 3 POISE Trial Met Primary Endpoint,2014-03-16 13:59:00-04:00,ICPT,neutral
651830.0,Intercept Reports Q4 EPS of $(0.64) vs $(0.70) Est,2014-03-14 18:06:00-04:00,ICPT,neutral
651831.0, BioBreakthrough's Tweet: $GLMD virgin NASH play likely to attract some serious attention as $ICPT tests all-time highs,2014-03-14 10:24:00-04:00,ICPT,positive
651832.0,"Morning Gainers for Friday, March 14, 2014",2014-03-14 10:09:00-04:00,ICPT,neutral
651833.0,"Biotech ETFs Flash Buy Signals (XBI, IBB, BBH, ICPT)",2014-03-13 14:15:00-04:00,ICPT,neutral
651834.0,"Shares of Intercept Pharma Rise as BofA Sees US, EU Regulators Giving A Thumbs Up",2014-03-10 17:11:00-04:00,ICPT,positive
651835.0,Intercept Spikes Higher,2014-02-25 10:55:00-05:00,ICPT,neutral
651836.0,Intercept Names Sanj K. Patel and Glenn Sblendorio to Board of Directors ,2014-02-18 06:54:00-05:00,ICPT,neutral
651837.0,Which Sector Produced 8 Of The 10 Top Percentage Gainers In 2014?,2014-02-11 15:29:00-05:00,ICPT,positive
651838.0,Market Wrap For February 10: Markets Cautious Ahead Of Yellen Testimony,2014-02-10 16:47:00-05:00,ICPT,negative
651839.0,"Rise in Intercept Shares May be Attributed to Report of 'A Double-Blind, Placebo-Controlled Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis'",2014-01-17 11:06:00-05:00,ICPT,negative
651840.0,Intercept Spikes Higher,2014-01-17 10:19:00-05:00,ICPT,neutral
651841.0,Market Wrap For January 15: Bulls Take Over As Economic Growth Remains Healthy,2014-01-15 16:45:00-05:00,ICPT,positive
651842.0,Mid-Morning Market Update: Markets Rise; Bank of America Profit Beats Estimates,2014-01-15 11:31:00-05:00,ICPT,positive
651843.0,Adam Feuerstein Tweet $ICPT mentions $RPTP and $GILD as NASH competitors. #JPM14,2014-01-15 11:06:00-05:00,ICPT,neutral
651844.0,"Intercept Pharma Shares Volatile as CEO Pruzanski Speaking at JP Morgan Healthcare Conf., Says Expecting OCA Final Results Issued in Q4",2014-01-15 10:41:00-05:00,ICPT,positive
651845.0,Benzinga's Top #PreMarket Gainers ,2014-01-15 08:08:00-05:00,ICPT,positive
651846.0,"Intercept Shares Rise 5% Pre-Market on Bank of America Reiteration of $872 PT, Buy Rating",2014-01-15 07:35:00-05:00,ICPT,positive
651847.0,Hearing Bank of America Reiterates Buy Rating and $872 PT on Intercept,2014-01-14 20:25:00-05:00,ICPT,neutral
651848.0,Market Wrap For January 14: Markets Rebound On Earnings Season Kickoff,2014-01-14 17:19:00-05:00,ICPT,neutral
651849.0,Mid-Afternoon Market Update: Markets Continue Rally as Tesla Guidance Lifts Stock,2014-01-14 15:53:00-05:00,ICPT,neutral
651850.0,Hearing BMO Defending ICPT,2014-01-14 13:25:00-05:00,ICPT,neutral
651851.0,Hearing Positive Comments from Summer Street on Intercept,2014-01-14 11:53:00-05:00,ICPT,positive
651852.0,Market Wrap For January 13: Markets Showing Weakness Ahead Of Major Earning Releases,2014-01-13 16:52:00-05:00,ICPT,negative
651853.0,Morning Market Losers ,2014-01-13 10:01:00-05:00,ICPT,negative
651854.0,Benzinga's Top #PreMarket Losers,2014-01-13 08:30:00-05:00,ICPT,negative
651855.0,"Intercept Shares Fall 31% in Pre-Market to $308.10, Following Late Friday WSJ Article: 'NIH Says Patients on Intercept Drug Had More 'Bad' Cholesterol'",2014-01-13 07:38:00-05:00,ICPT,positive
651856.0,Intercept Reports Additional Details About FLINT Clinical Trial of OCA in NASH Provided by NIDDK ,2014-01-12 18:55:00-05:00,ICPT,neutral
651857.0,Intercept Shares Fall $25 After-Hours on WSJ Article: 'NIH Says Patients on Intercept Drug Had More 'Bad' Cholesterol',2014-01-11 09:31:00-05:00,ICPT,positive
651858.0,"Intercept to Present at the JP Morgan Healthcare Conference on Wednesday, January 15, 2014 at 10:30 AM ET",2014-01-10 18:37:00-05:00,ICPT,positive
651859.0,Clovis Shares Spike Higher After-Hours on CNBC Comments it is Next Intercept,2014-01-10 17:28:00-05:00,ICPT,positive
651860.0,"Market Wrap For January 10: Job Growth Weak, But Unemployment Falls",2014-01-10 16:53:00-05:00,ICPT,negative
651861.0,Mid-Afternoon Market Update: Plug Rises on Secondary Pricing as Markets Remain Mixed Following Jobs Number,2014-01-10 15:51:00-05:00,ICPT,positive
651862.0,13G Filing from Visium Asset Mgmt on Intercept Pharma Shows Raised Stake from 3.97% Stake as of Sept. 30th to 5.3% Stake,2014-01-10 13:35:00-05:00,ICPT,positive
651863.0,Mid-Day Market Update: Abercrombie & Fitch Surges On Strong Outlook; Sears Shares Slip,2014-01-10 12:27:00-05:00,ICPT,positive
651864.0,Mid-Morning Market Update: Markets Drop; Alcoa Q4 Earnings Miss Estimates,2014-01-10 11:04:00-05:00,ICPT,negative
651865.0,Bank of America Reiterates on Intercept Pharmaceuticals,2014-01-10 10:54:00-05:00,ICPT,neutral
651866.0,Benzinga's Volume Movers,2014-01-10 10:26:00-05:00,ICPT,neutral
651867.0,Stocks Hitting 52-Week Highs,2014-01-10 10:17:00-05:00,ICPT,neutral
651868.0,Citi Maintains on Intercept Pharmaceuticals,2014-01-10 10:08:00-05:00,ICPT,neutral
651869.0,Benzinga's Top #PreMarket Gainers,2014-01-10 08:16:00-05:00,ICPT,positive
651870.0,"Bank of America Maintains Buy on Intercept, Raises PO to $872.00",2014-01-10 08:10:00-05:00,ICPT,negative
651871.0,"Oppenheimer Maintains Outperform on Intercept, Raises PT to $360.00",2014-01-10 07:32:00-05:00,ICPT,neutral
651872.0,"Citigroup Maintains Buy on Intercept, Raises PT to $400.00",2014-01-10 07:32:00-05:00,ICPT,neutral
651873.0,Market Wrap For January 9: All Eyes on Tomorrow's Job Report,2014-01-09 16:43:00-05:00,ICPT,neutral
651874.0,Mid-Afternoon Market Update: Markets Moving Sideways Ahead of Alcoa Report,2014-01-09 15:41:00-05:00,ICPT,neutral
651875.0,Mid-Day Market Update: U.S. Stocks Turn Red; Bed Bath & Beyond Shares Decline On Weak Q3 Earnings,2014-01-09 12:46:00-05:00,ICPT,negative
651876.0,Benzinga's Volume Movers,2014-01-09 10:28:00-05:00,ICPT,neutral
651877.0,Morning Market Movers ,2014-01-09 10:05:00-05:00,ICPT,neutral
651878.0,Benzinga's Top #PreMarket Gainers,2014-01-09 08:14:00-05:00,ICPT,positive
651879.0,"Intercept Shares Resume Trading, Now Up 119%",2014-01-09 08:03:00-05:00,ICPT,positive
651880.0,Shares of Intercept Pharma to Resume Trade at 8AM EST,2014-01-09 07:36:00-05:00,ICPT,positive
651881.0,UPDATE: Intercept Cites Highly Statistically Significant Improvement,2014-01-09 07:33:00-05:00,ICPT,positive
651882.0,"Intercept Reports Nash Primary Endpoint Met, FLINT Trial Has Been Stopped Early",2014-01-09 07:33:00-05:00,ICPT,negative
651883.0,Intercept Pharma Shares Halted News Pending,2014-01-09 07:29:00-05:00,ICPT,positive
651884.0,"Intercept Says Extended Term of Research Program with Servier to Sept. 30th, 2015",2014-01-02 16:46:00-05:00,ICPT,neutral
651885.0,Intercept Pharma Says Will Issue Update on Obeticholic Acid Program Jan. 9th,2014-01-02 16:09:00-05:00,ICPT,neutral
651886.0,13G Filing from SAC Capital on Intercept Pharma Shows 5.3% Stake,2013-11-08 16:19:00-05:00,ICPT,neutral
651887.0,"Intercept Pharmaceutical Shares Skyrocket after Oppenheimer's Data ""Optimism""",2013-10-24 15:33:00-04:00,ICPT,positive
651888.0,Intercept Prices 1.5M Share Offering at $62.50/Share,2013-10-09 06:01:00-04:00,ICPT,positive
651889.0,S-1 Filing from Intercept Pharma Shows Holders to Sell Shares,2013-10-01 16:10:00-04:00,ICPT,positive
651890.0,UPDATE: BMO Capital Markets Raises PT on Intercept Pharmaceuticals Following 2Q13 Operating Results,2013-08-14 11:14:00-04:00,ICPT,neutral
651891.0,UPDATE: Wedbush Raises PT on Intercept Pharmaceuticals Following In-Line Q2 Financials,2013-08-13 10:45:00-04:00,ICPT,neutral
651892.0,Intercept Reports Q2 EPS of $(0.79) vs $(0.51) Est; Revenue of $405.0K vs $400.0K Est,2013-08-13 06:19:00-04:00,ICPT,neutral
651893.0,"Citigroup Initiates Coverage on Intercept at Buy, Announces $60.00 PT",2013-08-12 06:38:00-04:00,ICPT,neutral
651894.0,"BMO Says Biotech Sector Could See Upside from M&A, Offers Multiple Attractive Targets",2013-07-02 12:29:00-04:00,ICPT,positive
651895.0,ViroPharma and Other Biotech Stocks Recommended by Oppenheimer (VPHM),2013-06-24 15:16:00-04:00,ICPT,positive
651896.0,Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares,2013-06-24 13:33:00-04:00,ICPT,positive
651897.0,UPDATE: Oppenheimer Initiates Intercept Pharmaceuticals at Outperform on Bullish Outlook,2013-06-21 08:30:00-04:00,ICPT,neutral
651898.0,"Oppenheimer Initiates Coverage on Intercept at Outperform, Announces $60.00 PT",2013-06-20 16:15:00-04:00,ICPT,neutral
651899.0,Mid-Afternoon Market Update: Markets Fall Following FOMC Statement; Adobe Remains on the Rise,2013-06-19 15:41:00-04:00,ICPT,neutral
651900.0,"Mid-Day Market Update: La-Z-Boy Drops On Q4 Results, Nektar Gains",2013-06-19 12:32:00-04:00,ICPT,positive
651901.0,"Mid-Morning Market Update: Markets Edge Lower, FedEx Posts Upbeat Profit",2013-06-19 10:32:00-04:00,ICPT,positive
651902.0,Intercept Pharmaceuticals Prices  1.73M Share Offering at $33.01/Share,2013-06-19 06:23:00-04:00,ICPT,positive
651903.0,Intercept Pharmaceuticals Announces 1.73M Share Offering,2013-06-17 06:45:00-04:00,ICPT,positive
651904.0,Intercept Pharma Registers Up to 2M Shares for ~$63.3M,2013-06-10 07:38:00-04:00,ICPT,positive
651905.0,Intercept Reports Q1 EPS of $(0.62) Which May Not Compare $(0.44) Est,2013-05-14 17:24:00-04:00,ICPT,neutral
651906.0,"Intercept Issues Added Results of Global Primary Biliary Cirrhosis Study, Says Ursodiol Failed to Meet Poise Endpoint in 59% of Patients",2013-04-30 08:17:00-04:00,ICPT,negative
651907.0,UPDATE: Wedbush Raises PT on Intercept Pharmaceuticals on Decreased Regulatory Risk,2013-04-15 11:48:00-04:00,ICPT,negative
651908.0,"Wedbush Maintains Outperform on Intercept, Raises PT to $56.00",2013-04-15 09:44:00-04:00,ICPT,neutral
651909.0,Intercept Reports Q4 EPS of $(2.02) Which May Not Compare $(0.34) Est,2013-03-18 16:31:00-04:00,ICPT,neutral
651910.0,Intercept Pharma Begins Phase 2 NASH Trial of OCA in Japan,2013-01-07 17:35:00-05:00,ICPT,neutral
651911.0,Intercept Pharmaceuticals Completes Enrollment in Phase 3 Primary Biliary Cirrhosis POISE Trial ,2012-12-19 07:07:00-05:00,ICPT,neutral
651912.0,UPDATE: Bank of America Initiates Intercept Pharmaceuticals at Buy on Regulatory Outlook  ,2012-11-12 07:14:00-05:00,ICPT,neutral
651913.0,"Bank of America Initiates Coverage on Intercept Pharmaceuticals at Buy, Announces PO of $29",2012-11-12 05:51:00-05:00,ICPT,negative
651914.0,"Intercept Pharma Announces OCA Well Tolerated, Says 5 Patients Met Primary Efficacy Point",2012-11-08 17:36:00-05:00,ICPT,positive
651915.0,"Wedbush Securities Initiates Coverage on Intercept Pharmaceuticals at Outperform, Announces PT of $25",2012-11-08 13:00:00-05:00,ICPT,positive
651916.0,UPDATE: BMO Capital Markets Initiates Intercept Pharmaceuticals at Outperform on Outlook  ,2012-11-05 12:56:00-05:00,ICPT,neutral
651917.0,Stocks Hitting 52-Week Lows,2012-11-01 10:28:00-04:00,ICPT,negative
651918.0,"Intercept Opens for Trading at $18.49, Priced at $15 per Share",2012-10-11 10:47:00-04:00,ICPT,positive
